

Excessive production of interleukin 6/B cell stimulatory

European Journal of Immunology

18, 1797-1802

DOI: [10.1002/eji.1830181122](https://doi.org/10.1002/eji.1830181122)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Interleukin-6 is a potent thrombopoietic factor in vivo in mice. <i>Blood</i> , 1989, 74, 1241-1244.	0.6	404
2	Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. <i>Blood</i> , 1989, 74, 1360-1367.	0.6	844
4	Current Concepts of B Cell Modulation. <i>International Reviews of Immunology</i> , 1989, 5, 97-109.	1.5	17
5	HEBERDEN ORATION, 1988 EXPLORING IMMUNE PATHWAY'S IN RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 1989, 28, 466-479.	0.9	9
6	Interleukin-6 and its receptor during homeostasis, inflammation, and tumor growth. <i>Klinische Wochenschrift</i> , 1989, 67, 697-706.	0.6	51
7	IL-6 GENE POLYMORPHISM IN RHEUMATOID ARTHRITIS, PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, AND IN HEALTHY DANES. <i>International Journal of Immunogenetics</i> , 1989, 16, 461-465.	1.2	31
8	Multifunctional cytokines in haemopoiesis. <i>Blood Reviews</i> , 1989, 3, 263-268.	2.8	9
9	The role of cytokines in the pathogenesis of rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 1989, 11, 123-62.	4.0	131
10	Rheumatoid Synovial Fluid Reconstitutes the B-Cell Defect in CBA/N Mice. <i>Scandinavian Journal of Immunology</i> , 1989, 30, 749-753.	1.3	8
11	Synovial Fluid from Rheumatoid Arthritis Patients Induces Polyclonal Antibody Formation in Vivo. <i>Scandinavian Journal of Immunology</i> , 1989, 30, 587-596.	1.3	12
12	Cytokine production in culture by cells isolated from the synovial membrane. <i>Journal of Autoimmunity</i> , 1989, 2, 177-186.	3.0	127
13	Interleukin 6 and plasma cell neoplasias. <i>Progress in Growth Factor Research</i> , 1989, 1, 133-142.	1.7	34
15	Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. <i>FEBS Letters</i> , 1989, 250, 607-610.	1.3	377
16	Establishment of strongly neutralizing monoclonal antibody to human interleukin-6 and its epitope analysis. <i>Biochemical and Biophysical Research Communications</i> , 1989, 165, 728-734.	1.0	57
17	Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium. <i>Clinical Immunology and Immunopathology</i> , 1989, 52, 238-247.	2.1	49
18	Structure and evolution of mouse interleukin 6 gene. <i>Molecular Immunology</i> , 1989, 26, 1021-1026.	1.0	6
19	INHIBITORY EFFECT OF TNF α ; ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS. <i>Lancet, The</i> , 1989, 334, 244-247.	6.3	853
20	IgG1 plasmacytosis in interleukin 6 transgenic mice.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 7547-7551.	3.3	580

#	ARTICLE	IF	CITATIONS
21	A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.. EMBO Journal, 1990, 9, 1897-1906.	3.5	1,383
22	Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene.. Molecular and Cellular Biology, 1990, 10, 2757-2764.	1.1	288
23	Interleukin-6 and the acute phase response. Biochemical Journal, 1990, 265, 621-636.	1.7	2,501
24	CD4+ T-Cell Clones from Autoimmune Thyroid Tissue Cannot be Classified According to their Lymphokine Production. Scandinavian Journal of Immunology, 1990, 32, 433-440.	1.3	40
25	Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro. British Journal of Haematology, 1990, 76, 476-483.	1.2	24
26	Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes. Cellular Immunology, 1990, 129, 95-103.	1.4	39
27	Role of endogenously produced interleukin-6 as a second signal in murine thymocyte proliferation induced by multiple cytokines: Regulatory effects of transforming growth factor- β 1. Cellular Immunology, 1990, 131, 261-271.	1.4	22
28	Interleukin 6 and its receptor in the immune response and hematopoiesis. International Journal of Cell Cloning, 1990, 8, 155-167.	1.6	25
29	The mechanism of cartilage degradation in osteoarthritic joints. Seminars in Arthritis and Rheumatism, 1990, 19, 16-20.	1.6	21
30	Pathophysiology of cytokines. Leukemia Research, 1990, 14, 675-677.	0.4	19
31	Proton nuclear magnetic resonance study of human interleukin 6: Chemical modifications and partial spectral assignments for the aromatic residues. BBA - Proteins and Proteomics, 1990, 1041, 243-249.	2.1	16
32	Interleukin 6 (IL-6). Biotherapy (Dordrecht, Netherlands), 1990, 2, 363-373.	0.7	24
34	Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis and Rheumatism, 1990, 33, 305-315.	6.7	903
35	Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis and Rheumatism, 1990, 33, 398-402.	6.7	163
36	How important are t cells in chronic rheumatoid synovitis?. Arthritis and Rheumatism, 1990, 33, 768-773.	6.7	472
37	Role of cytokines in inflammatory synovitis. Arthritis and Rheumatism, 1990, 33, 1776-1786.	6.7	130
38	Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. European Journal of Immunology, 1990, 20, 1927-1931.	1.6	68
39	Biological and clinical aspects of interleukin 6. Trends in Immunology, 1990, 11, 443-449.	7.5	1,038

#	ARTICLE	IF	CITATIONS
40	Induction of interleukin-6 during human immunodeficiency virus infection. <i>Blood</i> , 1990, 76, 2303-2310.	0.6	184
41	Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6. <i>Blood</i> , 1990, 76, 2493-2500.	0.6	90
42	IMMUNOGENETIC AND CELLULAR IMMUNE MECHANISMS IN RHEUMATOID ARTHRITIS: RELEVANCE TO NEW THERAPEUTIC STRATEGIES. <i>Rheumatology</i> , 1990, 29, 58-64.	0.9	29
43	Castleman's Disease and Interleukin 6. <i>Leukemia and Lymphoma</i> , 1990, 2, 369-380.	0.6	8
44	Functional murine interleukin 6 receptor with the intracisternal A particle gene product at its cytoplasmic domain. Its possible role in plasmacytomagenesis.. <i>Journal of Experimental Medicine</i> , 1990, 171, 2001-2009.	4.2	97
45	IL-6 in Synovial Fluids, Plasma and Supernatants from Cultured Cells of Patients with Rheumatoid Arthritis and Other Inflammatory Arthritides. <i>Scandinavian Journal of Rheumatology</i> , 1990, 19, 177-182.	0.6	26
46	Interleukin 6 in Infection and Cancer. <i>Experimental Biology and Medicine</i> , 1990, 195, 183-191.	1.1	59
47	Interleukin-6 enhances human Ig production, but not as a terminal differentiation factor for B lymphocytes. <i>Research in Immunology</i> , 1990, 141, 341-356.	0.9	8
48	Interleukin-6 release by rat liver macrophages. <i>Journal of Hepatology</i> , 1990, 11, 367-373.	1.8	56
49	IL 3 and IL 6 do not induce bone resorption in vitro. <i>Cytokine</i> , 1990, 2, 217-220.	1.4	29
50	Elevated serum interleukin-6 associated with a failur in B cell differentiation in common variable immunodeficiencyâ€. <i>Journal of Allergy and Clinical Immunology</i> , 1990, 86, 512-521.	1.5	33
51	An enzyme-linked immunosorbent assay for the measurement of human interleukin-6. <i>Journal of Immunological Methods</i> , 1990, 133, 279-284.	0.6	62
52	Peptide Growth Factors and Their Receptors I. <i>Handbook of Experimental Pharmacology</i> , 1990, , .	0.9	34
53	Activation of interleukin-6 gene expression through the NF-kappa B transcription factor.. <i>Molecular and Cellular Biology</i> , 1990, 10, 2327-2334.	1.1	1,267
54	Human Alveolar Macrophage and Blood Monocyte Interleukin-6 Production. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1990, 3, 497-505.	1.4	69
55	Interleukin-1 β induces synthesis and secretion of interleukin-6 in human chondrocytes. <i>FEBS Letters</i> , 1990, 263, 321-324.	1.3	58
56	Interleukin-6: An Overview. <i>Annual Review of Immunology</i> , 1990, 8, 253-278.	9.5	1,832
57	Significant increase of interleukin 6 production in blood mononuclear leukocytes obtained from patients with active imflammatory bowel disease. <i>Life Sciences</i> , 1990, 47, 2193-2197.	2.0	39

#	ARTICLE	IF	CITATIONS
58	Cerebrospinal fluid interleukin-6 activity in HIV infection and inflammatory and noninflammatory diseases of the nervous system. <i>Clinical Immunology and Immunopathology</i> , 1990, 57, 233-241.	2.1	62
59	Interleukin-6 serum levels correlate with footpad swelling in adjuvant-induced arthritic lewis rats treated with cyclosporin A or indomethacin. <i>Clinical Immunology and Immunopathology</i> , 1990, 56, 108-115.	2.1	43
60	Influence of IL-6 on Proliferation and Differentiation of Tonsillar Lymphocytes and Detection of IL-6 Producing Cells in Tonsil. <i>Acta Oto-Laryngologica</i> , 1991, 111, 245-253.	0.3	1
61	Molecular basis of new approaches to the therapy of rheumatoid arthritis. <i>Molecular Aspects of Medicine</i> , 1991, 12, 397-473.	2.7	7
62	Analysis of interleukin 6 (IL-6)/IL-6 receptor system using monoclonal anti-IL-6 antibodies. <i>Molecular Immunology</i> , 1991, 28, 1155-1161.	1.0	10
63	Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies. <i>Molecular Immunology</i> , 1991, 28, 1183-1192.	1.0	42
64	Diversification of the IgG molecule by oligosaccharides. <i>Molecular Immunology</i> , 1991, 28, 1369-1378.	1.0	67
65	Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 164, 1038-1043.	0.7	198
66	Molecular cloning and sequence of porcine interleukin 6 cDNA and expression of mRNA in synovial fibroblasts in vitro. <i>Cytokine</i> , 1991, 3, 269-276.	1.4	30
67	Regulation of the B cell response by cytokines. <i>Transfusion Science</i> , 1991, 12, 43-57.	0.6	0
68	Interleukin 6 inhibits human thyroid peroxidase gene expression. <i>European Journal of Endocrinology</i> , 1991, 124, 290-294.	1.9	48
69	Effect of synthesized constituents in the L-tryptophan product on the differentiation of eosinophils and the induction of IL-6: A possible cause of eosinophilia-myalgia syndrome. <i>Biochemical and Biophysical Research Communications</i> , 1991, 178, 1008-1013.	1.0	11
70	Site-specific mutagenesis of human interleukin-6 and its biological activity. <i>FEBS Letters</i> , 1991, 281, 167-169.	1.3	14
71	Hypogalactosylation of immunoglobulin G sugar chains and elevated serum interleukin 6 in Castleman's disease. <i>Clinica Chimica Acta</i> , 1991, 197, 221-228.	0.5	32
72	Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1991, 32, 67-74.	1.1	311
73	Cytokines and autoimmune disease. <i>Clinical Immunology and Immunopathology</i> , 1991, 61, 275-295.	2.1	74
74	Augmented interleukin 6 production by rat thyrocytes (FRTL5): Effect of interleukin 1β and thyroid-stimulating hormone. <i>Cytokine</i> , 1991, 3, 345-349.	1.4	21
75	Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice.. <i>Journal of Clinical Investigation</i> , 1991, 87, 739-742.	3.9	339

#	ARTICLE	IF	CITATIONS
76	Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. <i>Blood</i> , 1991, 77, 2413-2418.	0.6	117
77	Interleukin-6 mRNA and protein increase in vivo following induction of acute thrombocytopenia in mice. <i>Blood</i> , 1991, 77, 286-293.	0.6	24
78	Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.. <i>EMBO Journal</i> , 1991, 10, 4025-4031.	3.5	1,376
80	Interleukin-2, Autotolerance, and Autoimmunity. <i>Advances in Immunology</i> , 1991, 50, 147-235.	1.1	72
81	Alteration in progression of murine autoimmune disease by treatment with a novel immunomodulator, SM-8849. <i>International Journal of Immunopharmacology</i> , 1991, 13, 445-454.	1.1	4
82	Inhibition by cyclo-oxygenase inhibitors of interleukin-6 production by human peripheral blood mononuclear cells. <i>International Journal of Immunopharmacology</i> , 1991, 13, 1137-1146.	1.1	29
83	Monoclonal IgGs from an autoimmune MRL/Mp-lpr/lpr mouse induce an interleukin-3-dependent myeloid cell line to produce tumor necrosis factor α and interleukin-6. <i>Cellular Immunology</i> , 1991, 132, 1-9.	1.4	12
84	Interleukin 6 (IL-6) and its receptor: Their role in plasma cell neoplasias. <i>International Journal of Cell Cloning</i> , 1991, 9, 166-184.	1.6	110
85	Interleukin-6 production by human gingival fibroblasts. <i>Journal of Periodontal Research</i> , 1991, 26, 339-345.	1.4	132
86	Cytokine Assays: Role in Evaluation of the Pathogenesis of Autoimmunity. <i>Immunological Reviews</i> , 1991, 119, 105-123.	2.8	86
87	Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. <i>European Journal of Clinical Investigation</i> , 1991, 21, 479-484.	1.7	100
88	Chemical modification and 1H-NMR studies on the receptor-binding region of human interleukin 6. <i>FEBS Journal</i> , 1991, 196, 377-384.	0.2	24
89	Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor α . <i>European Journal of Immunology</i> , 1991, 21, 2575-2579.	1.6	288
90	Interactions between interleukin-1 and basic fibroblast growth factor on articular chondrocytes. Effects on cell growth, prostanoid production, and receptor modulation. <i>Arthritis and Rheumatism</i> , 1991, 34, 314-324.	6.7	26
91	T Lymphocyte Adhesion to Human Synovial Fibroblasts. Role of Cytokines and the Interaction Between Intercellular Adhesion Molecule 1 and CD11a/CD18. <i>Arthritis and Rheumatism</i> , 1991, 34, 1245-1253.	6.7	41
92	Case report: Interleukin-6 positive follicular hyperplasia in the lymph node of a patient with rheumatoid arthritis. <i>American Journal of Hematology</i> , 1991, 36, 282-284.	2.0	9
93	Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action. <i>Immunology Letters</i> , 1991, 28, 187-193.	1.1	64
94	Interleukin-6 in clinical medicine. <i>Annals of Hematology</i> , 1991, 62, 203-210.	0.8	129

#	ARTICLE	IF	CITATIONS
95	Significance of interleukin-6 in patients with inflammatory bowel disease. Gastroenterologia Japonica, 1991, 26, 20-28.	0.4	85
96	Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatology International, 1991, 11, 45-50.	1.5	85
97	INTERLEUKIN-6 ACTIVITY IN PAIRED SAMPLES OF SYNOVIAL FLUID. CORRELATION OF SYNOVIAL FLUID INTERLEUKIN-6 LEVELS WITH CLINICAL AND LABORATORY PARAMETERS OF INFLAMMATION. Rheumatology, 1991, 30, 186-189.	0.9	32
98	Neutrophils isolated from the synovial fluid of patients with rheumatoid arthritis: priming and activation in vivo.. Annals of the Rheumatic Diseases, 1991, 50, 147-153.	0.5	83
99	Role of Interleukin 6 in the Inflammatory Response After Cataract Surgery. JAMA Ophthalmology, 1991, 109, 1681.	2.6	51
100	Vascular endothelium, cytokines, and the pathogenesis of inflammatory synovitis.. Annals of the Rheumatic Diseases, 1991, 50, 828-832.	0.5	8
101	Activation of the neutrophil myeloperoxidase-H ₂ O ₂ system by synovial fluid isolated from patients with rheumatoid arthritis.. Annals of the Rheumatic Diseases, 1991, 50, 237-242.	0.5	53
102	Cytokines in Rheumatoid Arthritis. Annals of Medicine, 1991, 23, 219-223.	1.5	79
103	The Modulation of the Expression of IL-6 and Its Receptor in Human Osteoblasts <i>in Vitro</i> *. Endocrinology, 1991, 129, 1513-1520.	1.4	163
104	Interleukin 6 Activity in Pleural Effusion. Chest, 1992, 102, 1055-1059.	0.4	57
105	Effects of interleukin-6 on the expression of thyroid hormone-binding protein genes in cultured human hepatoblastoma-derived (Hep G2) cells.. Molecular Endocrinology, 1992, 6, 935-942.	3.7	48
106	Hodgkin and Reed-Sternberg Cells Express Interleukin 6 and Interleukin 6 Receptors. Leukemia and Lymphoma, 1992, 7, 297-303.	0.6	17
107	A PRELIMINARY STUDY ON THE EFFECT OF ALPHA-INTERFERON TREATMENT ON THE JOINT INFLAMMATION AND SERUM CALCIUM IN RHEUMATOID ARTHRITIS. Rheumatology, 1992, 31, 405-408.	0.9	15
108	Human B Lymphocytes: Phenotype, Proliferation, and Differentiation. Advances in Immunology, 1992, 52, 125-262.	1.1	223
109	CYTOKINE MEASUREMENTS IN BIOLOGICAL FLUIDS. Rheumatology, 1992, 31, 721-722.	0.9	10
110	Production and modulation of interleukin 6 synthesis by synoviocytes derived from patients with arthritic disease.. Annals of the Rheumatic Diseases, 1992, 51, 198-202.	0.5	26
111	Localisation of intrahepatic interleukin 6 in patients with acute and chronic liver disease.. Journal of Clinical Pathology, 1992, 45, 408-411.	1.0	37
112	CYTOKINE INTER-RELATIONSHIPS AND THEIR ASSOCIATION WITH DISEASE ACTIVITY IN ARTHRITIS. Rheumatology, 1992, 31, 725-733.	0.9	76

#	ARTICLE	IF	CITATIONS
113	IL-6 increases endothelial permeability in vitro.. Endocrinology, 1992, 131, 710-714.	1.4	304
114	Distinct Responses of Interleukin-6 and Other Laboratory Parameters to Treatment in a Patient with Polyarteritis Nodosa—A Case Report. Angiology, 1992, 43, 512-516.	0.8	6
116	Profile of Cytokines in Synovial Fluid Specimens from Patients with Arthritis. Interleukin 8 (IL-8) and IL-6 Correlate with Inflammatory Arthritides. Immunological Investigations, 1992, 21, 321-327.	1.0	36
117	Interleukin-6 Levels in the Plasma of Patients with Lymphoma. Leukemia and Lymphoma, 1992, 7, 123-129.	0.6	15
118	Long-Term Consequences of Interleukin-6 Overexpression in Transgenic Mice. DNA and Cell Biology, 1992, 11, 587-592.	0.9	64
119	RELATIONSHIP BETWEEN INTERLEUKIN 6, AGALACTOSYL IgG AND PRISTANE-INDUCED ARTHRITIS. Autoimmunity, 1992, 11, 247-254.	1.2	33
120	Activation of neutrophil reactive-oxidant production by synovial fluid from patients with inflammatory joint disease. Soluble and insoluble immunoglobulin aggregates activate different pathways in primed and unprimed cells. Biochemical Journal, 1992, 286, 345-351.	1.7	69
121	Plasma Interleukin-6 Levels in Continuous Ambulatory Peritoneal Dialysis and Hemodialysis Patients. Nephron, 1992, 61, 132-134.	0.9	34
122	The Biology of Interleukin-6. Chemical Immunology and Allergy, 1992, 51, 153-180.	1.7	33
123	Case Report: Distinctive Immune Abnormalities in a Patient with Procainamide-Induced Lupus and Serositis. American Journal of the Medical Sciences, 1992, 303, 99-104.	0.4	11
124	Direct and indirect effects of Porphyromonas gingivalis lipopolysaccharide on interleukin-6 production by human gingival fibroblasts. Oral Microbiology and Immunology, 1992, 7, 218-224.	2.8	41
125	Elevated interleukin-6 levels in peritoneal fluid of patients with pelvic pathology. Fertility and Sterility, 1992, 58, 302-306.	0.5	93
126	Cytokines in the Vitreous of Patients With Proliferative Diabetic Retinopathy. American Journal of Ophthalmology, 1992, 114, 731-736.	1.7	167
127	Rheumatoid arthritis synovial fluid enhances T cell effector functions. Journal of Autoimmunity, 1992, 5, 333-350.	3.0	2
128	Leukemia inhibitory factor (LIF): A growth factor with pleiotropic effects on bone biology. Progress in Growth Factor Research, 1992, 4, 337-353.	1.7	18
129	Interleukin-6 and its receptor in autoimmunity. Journal of Autoimmunity, 1992, 5, 123-132.	3.0	69
130	Interleukin-6 and its relation to inflammation and disease. Clinical Immunology and Immunopathology, 1992, 62, S60-S65.	2.1	184
131	Elevation of feline interleukin 6-like activity in feline immunodeficiency virus infection. Clinical Immunology and Immunopathology, 1992, 65, 207-211.	2.1	21

#	ARTICLE	IF	CITATIONS
132	Specific and non-specific autoreactive immunity. <i>Journal of Autoimmunity</i> , 1992, 5, 37-44.	3.0	5
133	Interleukin-6 and its receptor: a paradigm for cytokines. <i>Science</i> , 1992, 258, 593-597.	6.0	863
134	Interleukin 6 and autoimmunity and plasma cell neoplasias. <i>Research in Immunology</i> , 1992, 143, 759-763.	0.9	14
135	Interleukin 6: general biological properties and possible role in the neural and endocrine systems. <i>Advances in Neuroimmunology</i> , 1992, 2, 83-97.	1.8	11
136	Î±-MSH peptides inhibit acute inflammation induced in mice by rIL-1Î², rIL-6, rTNF-Î± and endogenous pyrogen but not that caused by LTB4, PAF and rIL-8. <i>Cytokine</i> , 1992, 4, 320-328.	1.4	74
137	Palindromic rheumatism: Part of or apart from the spectrum of rheumatoid arthritis. <i>American Journal of Medicine</i> , 1992, 93, 451-460.	0.6	82
138	Stimulation by interleukin-1 of interleukin-6 production by human periodontal ligament cells. <i>Archives of Oral Biology</i> , 1992, 37, 743-748.	0.8	49
139	A Nuclear Factor for the IL-6 Gene (NF-IL6). <i>Chemical Immunology and Allergy</i> , 1992, 51, 299-322.	1.7	18
140	Interleukin-6 Receptor and Signals. <i>Chemical Immunology and Allergy</i> , 1992, 51, 181-204.	1.7	11
141	Leukotriene B4 enhances interleukin-6 (IL-6) production and IL-6 messenger RNA accumulation in human monocytes in vitro: transcriptional and posttranscriptional mechanisms. <i>Blood</i> , 1992, 80, 1004-1011.	0.6	120
142	Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. <i>The Clinical Investigator</i> , 1992, 70, 22-27.	0.6	56
143	Elevated serum interleukin-6 levels in patients with acute hepatitis. <i>Journal of Clinical Immunology</i> , 1992, 12, 197-200.	2.0	46
144	IL-6 and NF-IL6 in Acute-Phase Response and Viral Infection. <i>Immunological Reviews</i> , 1992, 127, 25-50.	2.8	496
145	Use of Monoclonal Antibodies in vivo as a Therapeutic Strategy for Alloimmune or Autoimmune Reactivity: The Besancon Experience. <i>Immunological Reviews</i> , 1992, 129, 31-55.	2.8	22
146	Activation of HLA-DR and Interleukin-6 Gene Transcription in Resting T Cells via the CD2 Molecule: Relevance to Chronic Immune-Mediated Inflammation. <i>Scandinavian Journal of Immunology</i> , 1992, 36, 469-478.	1.3	10
147	Systemic and cutaneous plasmacytosis with multiple skin lesions and polyclonal hypergammaglobulinaemia: significant serum interleukin-6 levels. <i>British Journal of Dermatology</i> , 1992, 127, 49-53.	1.4	56
148	Interleukin-6 can prime THP-1 macrophages for enhanced production of tumor necrosis factor-Î± in response to LPS. <i>Immunopharmacology</i> , 1992, 23, 97-103.	2.0	12
149	Interleukin-6 (IL-6) in adjuvant arthritis of rats and its pharmacological modulation. <i>International Journal of Immunopharmacology</i> , 1992, 14, 565-571.	1.1	39

#	ARTICLE	IF	CITATIONS
150	Contribution of synovial mesenchymal cells to the pathogenesis of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1992, 21, 267-273.	1.6	27
151	Interleukin 6: presence and future. <i>International Journal of Clinical and Laboratory Research</i> , 1992, 22, 143-151.	1.0	43
152	The M20 IL-1 inhibitor prevents onset of adjuvant arthritis. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1992, 4, 317-323.	0.7	10
153	Effect of anticancer drugs on the release of interleukin-6 in vitro. <i>Cancer Immunology, Immunotherapy</i> , 1992, 34, 228-232.	2.0	8
154	Intervention with immunomodulatory agents: new pharmacological developments. <i>Bailliere's Clinical Rheumatology</i> , 1992, 6, 455-484.	1.0	6
155	Purification and characterization of a recombinant murine interleukin-6. Isolation of N- and C-terminally truncated forms. <i>FEBS Journal</i> , 1992, 207, 903-913.	0.2	48
156	Glycosylation of interleukin-6 purified from normal human blood mononuclear cells. <i>FEBS Journal</i> , 1992, 203, 135-141.	0.2	32
157	The importance of the t cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1992, 35, 729-735.	6.7	462
158	Leukemia inhibitory factor/differentiation-stimulating factor (LIF/D-factor): Regulation of its production and possible roles in bone metabolism. <i>Journal of Cellular Physiology</i> , 1992, 152, 71-78.	2.0	64
159	Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. <i>European Journal of Immunology</i> , 1992, 22, 1989-1993.	1.6	93
160	Plasma cytokine levels in thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 1992, 40, 167-170.	2.0	50
161	The effect of interleukin-1 on cytokine gene expression in cultured human articular chondrocytes analyzed by messenger rna phenotyping. <i>Arthritis and Rheumatism</i> , 1993, 36, 35-43.	6.7	19
162	Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. regulation of its production in synovial cells by interleukin-1 and tumor necrosis factor. <i>Arthritis and Rheumatism</i> , 1993, 36, 762-771.	6.7	110
163	Elevated synovial fluid levels of interleukin-6 and tumor necrosis factor associated with early experimental canine osteoarthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 819-826.	6.7	85
164	Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor $\hat{\pm}$. <i>Arthritis and Rheumatism</i> , 1993, 36, 1681-1690.	6.7	1,000
165	Expressions of cytokine genes during development of autoimmune sialadenitis in MRL/lpr mice. <i>European Journal of Immunology</i> , 1993, 23, 2387-2391.	1.6	58
166	Enhanced expression of interleukin 6 in rat and murine arthritis models. <i>International Journal of Immunopharmacology</i> , 1993, 15, 469-476.	1.1	32
167	Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis $\hat{\pm}$ Suppressive effect of TA-383 on interleukin 6 production. <i>International Journal of Immunopharmacology</i> , 1993, 15, 515-519.	1.1	12

#	ARTICLE	IF	CITATIONS
168	Transcriptional activation of the interleukin-6 gene by HTLV-1 p40tax through an NF- κ B-like binding site. <i>Immunology Letters</i> , 1993, 37, 159-165.	1.1	29
169	Interleukin-6 in autoimmune diseases. <i>The Clinical Investigator</i> , 1993, 71, 664-71.	0.6	42
170	Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. <i>Rheumatology International</i> , 1993, 13, 45-51.	1.5	116
171	Increased Interleukin 6 Production by T Cells Derived from Patients with Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 1993, 100, 299-304.	0.3	78
172	Contrasting levels of <i>in vitro</i> cytokine production by rheumatoid synovial tissues demonstrating different patterns of mononuclear cell infiltration. <i>Clinical and Experimental Immunology</i> , 2008, 93, 387-395.	1.1	34
173	Gingival fluid IL-1 and IL-6 levels in refractory periodontitis. <i>Journal of Clinical Periodontology</i> , 1993, 20, 225-231.	2.3	165
174	Specific covalent modification of the tryptophan residues in murine interleukin-6. Effect on biological activity and conformational stability. <i>FEBS Journal</i> , 1993, 217, 53-59.	0.2	6
175	High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. <i>British Journal of Haematology</i> , 1993, 83, 433-441.	1.2	95
176	The regulation of megakaryocyte polyploidization and its implications for coronary artery occlusion. <i>European Journal of Clinical Investigation</i> , 1993, 23, 1-9.	1.7	13
177	Elevated production of interleukin 6 by hepatic MNC correlates with ICAM-1 expression on the hepatic sinusoidal endothelial cells in autoimmune MRL/lpr mice. <i>Immunology Letters</i> , 1993, 36, 145-152.	1.1	24
178	Elevated levels of TNF in the joints of adjuvant arthritic rats. <i>Cytokine</i> , 1993, 5, 298-304.	1.4	61
179	Selective presence of IgG2b inducing factor in synovial fluid of patients with rheumatoid arthritis. <i>Cytokine</i> , 1993, 5, 589-594.	1.4	4
180	The effects of calcium pentosan polysulfate on inflammatory mediators in the rat air-pouch model of inflammation. <i>Current Therapeutic Research</i> , 1993, 54, 714-730.	0.5	10
181	Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 1286-1294.	6.7	298
182	3 Endometriosis: The host response. <i>Bailliere's Clinical Obstetrics and Gynaecology</i> , 1993, 7, 701-713.	0.6	32
183	Increased serum interleukin-6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 213-218.	1.8	59
184	Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: Synergism with IL-1 β and TNF α . <i>Journal of Neuroimmunology</i> , 1993, 47, 73-81.	1.1	116
185	Cytokines in the peritoneal fluid of patients with endometriosis. <i>International Journal of Gynecology and Obstetrics</i> , 1993, 43, 45-50.	1.0	64

#	ARTICLE	IF	CITATIONS
186	Preparation of monoclonal antibodies against the IL-6 signal transducer, gp130, that can inhibit IL-6-mediated functions. <i>Journal of Immunological Methods</i> , 1993, 163, 217-223.	0.6	46
187	Interleukin-6 inhibits bone formation in vitro. <i>Bone and Mineral</i> , 1993, 21, 21-28.	2.0	130
188	Interleukin-6 in Biology and Medicine. <i>Advances in Immunology</i> , 1993, 54, 1-78.	1.1	1,191
189	The Cytokines: Physiological and Pathophysiological Aspects. <i>Advances in Clinical Chemistry</i> , 1993, 30, 1-88.	1.8	13
190	A reappraisal of the evidence that rheumatoid arthritis and several other idiopathic diseases are slow bacterial infections.. <i>Annals of the Rheumatic Diseases</i> , 1993, 52, S30-S38.	0.5	27
191	The Validity of Surrogate Markers in Rheumatic Disease. <i>Rheumatology</i> , 1993, 32, 3-8.	0.9	41
192	Involvement of CGRP, Substance P and Blood Circulation in Aggravating Mechanism of Absolute Ethanol-Induced Antral Lesions by Capsaicin Treatment in Rats. <i>The Japanese Journal of Pharmacology</i> , 1993, 61, 291-298.	1.2	5
193	Effects of Cholesterol Loading on Autoimmune MRL-lpr/lpr Mice: Susceptibility to Hypercholesterolemia and Aortic Cholesterol Deposition. <i>The Japanese Journal of Pharmacology</i> , 1993, 62, 175-181.	1.2	24
194	Molecular Cloning of Feline Interleukin-6 cDNA.. <i>Journal of Veterinary Medical Science</i> , 1993, 55, 941-944.	0.3	11
195	Cytokines as Therapeutic and Diagnostic Agents. <i>Tumor Biology</i> , 1993, 14, 69-94.	0.8	10
196	Distinct Responses of Interleukin-6 and Other Laboratory Parameters to Treatment in a Patient with Wegener's Granulomatosis.. <i>Internal Medicine</i> , 1993, 32, 189-192.	0.3	7
197	Serum Levels of Interleukin 6 in Patients with Pustulosis Palmaris et Plantaris. <i>Journal of Dermatology</i> , 1993, 20, 763-766.	0.6	15
198	Marrow B-Cell Precursors Are Increased in Lymphomas or Systemic Diseases Associated With B-Cell Dysfunction. <i>American Journal of Clinical Pathology</i> , 1993, 100, 60-66.	0.4	20
199	Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 11924-11928.	3.3	778
200	Differential mRNA Expression and Production of Interleukin-6 in Placental Trophoblast and Villous Core Compartments. <i>American Journal of Reproductive Immunology</i> , 1993, 30, 131-135.	1.2	26
202	Stimulation of interleukin-6 and prostaglandin E2 secretion from peritoneal macrophages by polymers of albumin. <i>Blood</i> , 1993, 82, 2853-2864.	0.6	23
203	CYTOKINES IN BONE. , 1993, , 375-412.		12
204	Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. <i>Blood</i> , 1994, 83, 2587-2593.	0.6	107

#	ARTICLE	IF	CITATIONS
205	Cytokine Reduction in the Treatment of Joint Conditions. <i>Mediators of Inflammation</i> , 1994, 3, 243-256.	1.4	21
206	Assessment of Interleukin-6 in the Pathogenesis of Periodontal Disease. <i>Journal of Periodontology</i> , 1994, 65, 147-153.	1.7	161
207	Elevated Cytokine Levels in Synovial Fluid of Rheumatoid Arthritis Correlates with the Presence of Cytomegalovirus Genome. <i>Autoimmunity</i> , 1994, 17, 333-337.	1.2	13
208	Synovial tissue macrophages and joint erosion in rheumatoid arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1994, 53, 39-44.	0.5	163
209	Interleukin-6 in Multiple Myeloma: Correlation with Disease Activity and Ki-67 Proliferation Index. <i>Leukemia and Lymphoma</i> , 1994, 12, 265-271.	0.6	33
210	Interleukin-6. <i>BioDrugs</i> , 1994, 2, 278-294.	0.7	1
211	Cytokines and Acute Phase Proteins in Rheumatoid Arthritis. <i>Scandinavian Journal of Rheumatology</i> , 1994, 23, 9-19.	0.6	67
212	Serum amyloid A is a sensitive marker of reduced activity in arthritic hamsters. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1994, 1, 165-173.	1.4	3
213	Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor. <i>Cancer</i> , 1994, 73, 53-57.	2.0	32
214	Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. <i>Cancer</i> , 1994, 73, 1882-1888.	2.0	156
215	Transforming Growth Factor β 1 Regulates Tissue Inhibitor of Metalloproteinases-1 Expression in Differentiated Human Articular Chondrocytes. <i>Arthritis and Rheumatism</i> , 1994, 37, 395-405.	6.7	92
216	Association between fever and serum interleukin-6 levels in children with group a β -hemolytic streptococcal infection. <i>Journal of Thermal Biology</i> , 1994, 19, 91-96.	1.1	1
217	Glycoconjugates in autoimmunity. <i>BBA - Biomembranes</i> , 1994, 1197, 237-255.	7.9	18
218	Glycoconjugates in autoimmunity. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1994, 1197, 237-255.	2.4	13
219	Induction of proto-oncogene and cytokine expression in human peripheral blood monocytes and the monocytic cell line THP-1 after stimulation with mycoplasma-derived material MDHM. <i>Leukemia Research</i> , 1994, 18, 319-325.	0.4	11
220	T-cell antigen receptors in rheumatoid arthritis. <i>Immunologic Research</i> , 1994, 13, 117-138.	1.3	19
221	RHEUMATOID NEUTROPHILIC DERMATITIS. <i>International Journal of Dermatology</i> , 1994, 33, 798-800.	0.5	37
222	Pathogenesis of Sjögren's syndrome-like autoimmune lesions in MRL/lpr mice. <i>Pathology International</i> , 1994, 44, 559-568.	0.6	33

#	ARTICLE	IF	CITATIONS
223	The value of C-reactive protein measurement in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1994, 24, 91-104.	1.6	115
224	Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness. <i>Psychiatry Research</i> , 1994, 51, 1-10.	1.7	220
225	Role of Cytokines in the Pathogenesis of Monoclonal Gammopathies. <i>Mayo Clinic Proceedings</i> , 1994, 69, 691-697.	1.4	21
226	Cytokines and systemic sclerosis. <i>Clinics in Dermatology</i> , 1994, 12, 407-417.	0.8	31
227	Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. <i>American Journal of Medicine</i> , 1994, 97, 374-378.	0.6	113
228	The involvement of bradykinin B ₁ and B ₂ receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. <i>British Journal of Pharmacology</i> , 1994, 113, 63-68.	2.7	133
229	Circadian rhythm of serum interleukin-6 in rheumatoid arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1994, 53, 521-524.	0.5	181
230	Immunoregulatory role of interleukin 10 in rheumatoid arthritis.. <i>Journal of Experimental Medicine</i> , 1994, 179, 1517-1527.	4.2	497
231	Significance of Interleukin 6 in Patients With Sarcoidosis. <i>Chest</i> , 1994, 106, 156-160.	0.4	35
232	Interleukin-6 Transgenic Mice and Pathogenesis of Myeloma/plasmacytoma.. <i>Proceedings of the Japanese Society of Animal Models for Human Diseases</i> , 1994, 10, 13-18.	0.1	0
233	ORIGIN OF HETEROGENEITY OF INTERLEUKIN-6 (IL-6) LEVELS IN MALIGNANT PLEURAL EFFUSIONS. <i>Oncology Reports</i> , 1994, 1, 507-11.	1.2	13
234	BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-B-cell growth.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 5325-5329.	3.3	161
235	Agalactosyl glycoforms of IgG autoantibodies are pathogenic.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 6123-6127.	3.3	248
236	Selection of Patients with Monoclonal Grammopathy of Undetermined Significance is Mandatory for a Reliable Use of Interleukin-6 and Other Nonspecific Multiple Myeloma Serum Markers. <i>Acta Haematologica</i> , 1994, 92, 1-7.	0.7	5
237	Inflammatory mediators increase surface expression of integrin ligands, adhesion to lymphocytes, and secretion of interleukin 6 in mouse Sertoli cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 5808-5812.	3.3	97
238	Detection of Cytokine Expression in Human Palatine Tonsils. <i>Practica Otologica, Supplement</i> , 1995, 1995, 99-104.	0.0	0
239	Fatal Diarrhea in a Patient with Castleman's Disease Associated with Intestinal Amyloidosis.. <i>Internal Medicine</i> , 1995, 34, 1106-1109.	0.3	16
240	Cytokine expression in chronic inflammatory disease. <i>British Medical Bulletin</i> , 1995, 51, 368-384.	2.7	111

#	ARTICLE	IF	CITATIONS
241	Beneficial effects of tumour necrosis factor-alpha (TNF- α) blockade in rheumatoid arthritis (RA). <i>Clinical and Experimental Immunology</i> , 1995, 101, 207-212.	1.1	117
242	Successful Treatment of Severe Arthralgia Associated with Palmoplantar Pustulosis with Low-Dose Oral Cyclosporine A. <i>Journal of Dermatology</i> , 1995, 22, 512-514.	0.6	13
243	Anti-cytokine therapy in rheumatoid arthritis. <i>Bailliere's Clinical Rheumatology</i> , 1995, 9, 633-652.	1.0	32
244	Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. <i>American Journal of Hematology</i> , 1995, 50, 237-243.	2.0	30
245	An interleukin-6 transgene expressed in B lymphocyte lineage cells overcomes the T cell-dependent establishment of normal levels of switched immunoglobulin isotypes. <i>European Journal of Immunology</i> , 1995, 25, 1332-1337.	1.6	22
246	IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: Promotion of IL6 receptor expression by EBV. <i>Hematological Oncology</i> , 1995, 13, 121-130.	0.8	20
247	Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. <i>Archives of Dermatological Research</i> , 1995, 287, 193-197.	1.1	112
248	Monoclonal anti-TNFalpha Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease. <i>Immunological Reviews</i> , 1995, 144, 195-223.	2.8	225
250	Recombinant human interleukin-6: safety issues of a pleiotropic growth factor. <i>Toxicology</i> , 1995, 105, 91-107.	2.0	25
251	Collagen induces cytokine production by synovial fluid mononuclear cells in rheumatoid arthritis. <i>Immunology Letters</i> , 1995, 45, 13-17.	1.1	10
252	Interferon- β -activated macrophages release interleukin-1 α to increase tube formation from endothelial cells of rat aorta. <i>Immunopharmacology</i> , 1995, 31, 93-101.	2.0	10
253	Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. <i>Digestive Diseases and Sciences</i> , 1995, 40, 949-959.	1.1	145
254	Detection and analysis of an alternatively spliced isoform of interleukin-6 mRNA in peripheral blood mononuclear cells. <i>Blood</i> , 1995, 86, 4559-4567.	0.6	35
255	Aetiopathogenesis of Rheumatoid Arthritis. , 1995, , 25-46.		6
256	RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation.. <i>EMBO Journal</i> , 1995, 14, 1187-1197.	3.5	226
257	Effects of triazolodiazepine on the production of interleukin-6 from murine spleen cells and rabbit synovial cells in vitro. <i>Mediators of Inflammation</i> , 1995, 4, 130-132.	1.4	1
258	Periarticular osteopenia in adjuvant induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells.. <i>Annals of the Rheumatic Diseases</i> , 1995, 54, 484-490.	0.5	19
259	Lipopolysaccharide-Mediated Induction of the Bovine Interleukin-6 Gene in Monocytes Requires Both NF- κ B and C/EBP Binding Sites. <i>DNA and Cell Biology</i> , 1995, 14, 795-802.	0.9	32

#	ARTICLE	IF	CITATIONS
260	Endothelin-induced interleukin-6 production by rat aortic endothelial cells.. Endocrinology, 1995, 136, 132-137.	1.4	45
261	INTERLEUKIN-6 (IL-6) INDUCES THE PROLIFERATION OF SYNOVIAL FIBROBLASTIC CELLS IN THE PRESENCE OF SOLUBLE IL-6 RECEPTOR. Rheumatology, 1995, 34, 321-325.	0.9	184
262	Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis.. Annals of the Rheumatic Diseases, 1995, 54, 654-661.	0.5	150
263	Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics, 1995, 26, 527-534.	1.3	197
264	TNF? Is an Effective Therapeutic Target for Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 1995, 766, 272-278.	1.8	73
265	ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS. Annual Review of Immunology, 1996, 14, 397-440.	9.5	2,301
266	Interleukin-6 (IL-6) in patients with Behçet's disease. Journal of Dermatological Science, 1996, 11, 189-195.	1.0	57
267	A child who was feverish for 2 years. Lancet, The, 1996, 348, 724.	6.3	3
268	Anti-inflammatory effects ofStephania tetrandraS. Moore on interleukin-6 production and experimental inflammatory disease models. Mediators of Inflammation, 1996, 5, 280-291.	1.4	17
269	Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.. Journal of Clinical Investigation, 1996, 97, 2672-2679.	3.9	499
270	Expression of HLA-DR and Cytokine Genes on Interferon-γ-Stimulated Human Salivary Gland Cell Line. Pathobiology, 1996, 64, 255-261.	1.9	12
272	Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 4885-4890.	3.3	278
273	Evaluation of interleukin-6 in rheumatoid arthritis as an activity criterion. Rheumatology International, 1996, 16, 141-144.	1.5	3
274	Effect of IL-10 on collagen-induced arthritis in mice. Inflammation Research, 1996, 45, 283-288.	1.6	86
275	Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease including magnetic resonance imaging and bone mineral density measurements. Arthritis and Rheumatism, 1996, 39, 504-514.	6.7	24
276	Elevated levels of the soluble form of bone marrow stromal cell antigen 1 in the sera of patients with severe rheumatoid arthritis. Arthritis and Rheumatism, 1996, 39, 629-637.	6.7	38
277	The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis and Rheumatism, 1996, 39, 1693-1702.	6.7	86
278	Interleukin 6 in diseases: Cause or cure?. Immunopharmacology, 1996, 31, 131-150.	2.0	18

#	ARTICLE	IF	CITATIONS
279	Thymus-dependent effects of a traditional chinese medicine, ren-shen-yang-rong-tang (Japanese name;) Tj ETQq0 0 0 rgBT /Overlock 10 1996, 18, 271-279.	1.1	10
280	A sigma ligand, SR 31747A, potently modulates Staphylococcal enterotoxin B-induced cytokine production in mice. Immunology, 1996, 88, 389-393.	2.0	23
281	Induction of a Proinflammatory Cytokine Network by <i>Mycoplasma arthritidis</i> -Derived Superantigen (MAS). Journal of Interferon and Cytokine Research, 1996, 16, 861-868.	0.5	24
282	Transcriptional Induction of Cyclooxygenase-2 in Osteoblasts Is Involved in Interleukin-6-Induced Osteoclast Formation*. Endocrinology, 1997, 138, 2372-2379.	1.4	130
283	B cell activation in patients with rheumatic disease: association with an increased ratio of Th2: Th1 cytokine secreting cells. Japanese Journal of Rheumatology, 1997, 7, 145-152.	0.0	0
284	Regulation of Macrophage Cytokine Production by Prostaglandin E2. Journal of Biological Chemistry, 1997, 272, 25693-25699.	1.6	177
285	Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease- modifying anti-rheumatic drugs. British Journal of Rheumatology, 1997, 36, 1298-1303.	2.5	54
286	Cytokines Involved in B-Cell Differentiation and Their Sites of Action. Experimental Biology and Medicine, 1997, 215, 121-133.	1.1	59
287	Gliostatin/platelet-derived endothelial cell growth factor as a clinical marker of rheumatoid arthritis and its regulation in fibroblast-like synoviocytes. British Journal of Rheumatology, 1997, 36, 315-321.	2.5	31
288	Modulation of hu/mu severe combined immunodeficient (SCID) mouse arthritis by local application of human recombinant IL-1 β , IL-2 and IL-6. Clinical and Experimental Immunology, 1997, 107, 96-102.	1.1	5
289	Biochemical Characterization of Glycyrrhizin as an Effective Inhibitor for Hyaluronidases from Bovine Testis.. Biological and Pharmaceutical Bulletin, 1997, 20, 973-977.	0.6	42
290	Co-Existence of Non-Hodgkin's Lymphoma in the Leukemic Phase and Polyarthritis Simulating Rheumatoid Arthritis.. Internal Medicine, 1997, 36, 227-231.	0.3	10
291	Anti-Tumor Necrosis Factor- α Therapy of Rheumatoid Arthritis. Advances in Immunology, 1997, 64, 283-350.	1.1	204
292	The therapeutic potential of interleukin-6 hyperagonists and antagonists. Expert Opinion on Investigational Drugs, 1997, 6, 237-266.	1.9	22
293	Inhibition of IL-1-Induced IL-6 Production by Synthetic Retinoids. Biochemical and Biophysical Research Communications, 1997, 231, 243-248.	1.0	40
294	A New Mechanism of Bone Destruction in Rheumatoid Arthritis: Synovial Fibroblasts Induce Osteoclastogenesis. Biochemical and Biophysical Research Communications, 1997, 240, 279-286.	1.0	181
295	Interleukin-6. Growth Factors and Cytokines in Health and Disease, 1997, 2, 201-256.	0.2	0
296	Production of Interleukin-6 Induced by Hypoxia Linked to Peripheral Arterial Disease. Annals of the New York Academy of Sciences, 1997, 811, 542-548.	1.8	4

#	ARTICLE	IF	CITATIONS
297	Mycoplasma salivarium induces interleukin-6 and interleukin-8 in human gingival fibroblasts. FEMS Immunology and Medical Microbiology, 1997, 19, 275-283.	2.7	39
298	Cytokine and nitric oxide production in the acute phase of bacterial cell wall-induced arthritis. Inflammation, 1997, 21, 113-131.	1.7	27
299	New Insights into the Pathogenesis and Treatment of Rheumatoid Arthritis. Clinical Immunology and Immunopathology, 1997, 83, 103-116.	2.1	49
300	B cell activation in patients with rheumatic disease: association with an increased ratio of Th2: Th1 cytokine secreting cells. Japanese Journal of Rheumatology, 1997, 7, 145-152.	0.0	0
301	Some plasma component is essential for IL-6 secretion by Neutrophils. Environmental Health and Preventive Medicine, 1997, 2, 89-92.	1.4	8
302	Osteoporosis in rheumatoid arthritis. Osteoporosis International, 1997, 7, 217-222.	1.3	43
303	Interleukin-6: Structure-function relationships. Protein Science, 1997, 6, 929-955.	3.1	347
304	Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Trends in Immunology, 1997, 18, 320-324.	7.5	334
305	IgG2b Inducing Factor from Rheumatoid Arthritis Synovial Fluid Activates Antibody Production in Highly Purified Mouse B Lymphocytes. Scandinavian Journal of Immunology, 1997, 45, 43-49.	1.3	1
306	Pristane-induced arthritis is CD4 + T cell dependent. Immunology, 1997, 90, 81-86.	2.0	34
307	Oncostatin M stimulates monocyte chemoattractant protein-1- and interleukin-1-induced matrix metalloproteinase-1 production by human synovial fibroblasts in vitro. Arthritis and Rheumatism, 1997, 40, 2139-2146.	6.7	79
308	Correlation of inflammatory cytokines with arthroscopic findings in patients with temporomandibular joint internal derangements. Journal of Oral and Maxillofacial Surgery, 1998, 56, 534-543.	0.5	129
309	Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis and Rheumatism, 1998, 41, 1388-1397.	6.7	99
310	TNF- α induces the transcription factor Egr-1, pro-inflammatory cytokines and cell proliferation in human skin fibroblasts and synovial lining cells. Rheumatology International, 1998, 17, 185-192.	1.5	37
311	Osteoclast biology. Importance in bone metastases. Der Orthopade, 1998, 27, 214-223.	0.7	0
312	Role of pro-inflammatory cytokines in rheumatoid arthritis. Seminars in Immunopathology, 1998, 20, 133-147.	4.0	127
313	Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Seminars in Immunopathology, 1998, 20, 247-259.	4.0	130
314	Synovial Fluid Cytokines in Patients with Rheumatoid Arthritis or Other Arthritic Lesions. Scandinavian Journal of Immunology, 1998, 48, 286-292.	1.3	95

#	ARTICLE	IF	CITATIONS
315	IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clinical and Experimental Immunology, 1998, 112, 397-402.	1.1	132
316	Inhibitory effects of anti-rheumatic drugs containing magnosalin, a compound from `Shin-i' (Flos) Tj ETQq1 1 0.784314 rgBT /Overlock Immunopharmacology, 1998, 39, 139-147.	2.0	16
317	Cytokines serum levels as the markers of thyroid activation in Graves' disease. Immunology Letters, 1998, 60, 143-148.	1.1	18
318	Matrix Metalloproteinase MMP-19 (RASI-1) is Expressed on the Surface of Activated Peripheral Blood Mononuclear Cells and is Detected as an Autoantigen in Rheumatoid Arthritis. Immunobiology, 1998, 198, 408-423.	0.8	81
319	Stimulatory effect of interleukin-6 on plasminogen activator activity from human dental pulp cells. Journal of Endodontics, 1998, 24, 331-334.	1.4	16
320	Interleukin 6 and its Receptor: Ten Years Later. International Reviews of Immunology, 1998, 16, 249-284.	1.5	696
321	Differential Cytokine mRNA Expression in Human Labial Minor Salivary Glands in Primary Sjögren's Syndrome. Autoimmunity, 1998, 28, 125-137.	1.2	51
322	The Pathophysiologic Roles of Interleukin-6 in Human Disease. Annals of Internal Medicine, 1998, 128, 127.	2.0	946
323	Establishment and Characterization of a Novel Human Rheumatoid Fibroblast-Like Synoviocyte Line, MH7A, Immortalized with SV40 T Antigen. Journal of Biochemistry, 1998, 124, 1153-1162.	0.9	118
324	Tumor Necrosis Factor- α Induces Interleukin-6 Production and Integrin Ligand Expression by Distinct Transduction Pathways. Journal of Biological Chemistry, 1998, 273, 7566-7571.	1.6	99
325	Transcriptional Roles of CCAAT/Enhancer Binding Protein- β , Nuclear Factor- κ B, and C-promoter Binding Factor 1 in Interleukin (IL)-1 β -induced IL-6 Synthesis by Human Rheumatoid Fibroblast-like Synoviocytes. Journal of Biological Chemistry, 1998, 273, 7620-7627.	1.6	66
326	Novel pathophysiological aspects of macrophage migration inhibitory factor (review).. International Journal of Molecular Medicine, 1998, 2, 17-28.	1.8	76
327	The Relationship Between Concentrations of Proinflammatory Cytokines Within Gingiva and the Adjacent Sulcular Depth. Journal of Periodontology, 1998, 69, 865-871.	1.7	67
328	Nitric Oxide Mediates Interleukin-1-Induced Gene Expression of Matrix Metalloproteinases and Basic Fibroblast Growth Factor in Cultured Rabbit Articular Chondrocytes. Journal of Biochemistry, 1998, 123, 431-439.	0.9	246
330	The Role of Cytokines in Autoimmunity. , 1999, 1, 56-71.		9
331	Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology, 1999, 38, 714-720.	0.9	86
332	Autoimmunity Is a Type I Interferon-Deficiency Syndrome Corrected by Ingested Type I IFN via the GALT System. Journal of Interferon and Cytokine Research, 1999, 19, 841-852.	0.5	14
333	Detection of interleukin-6 in human dental pulp and periapical lesions. Dental Traumatology, 1999, 15, 26-27.	0.8	126

#	ARTICLE	IF	CITATIONS
334	Structural mechanisms of bone loss in iliac biopsies: comparison between rheumatoid arthritis and postmenopausal osteoporosis. <i>Rheumatology International</i> , 1999, 18, 193-200.	1.5	13
335	Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. <i>Translational Research</i> , 1999, 133, 566-574.	2.4	45
336	Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. <i>Arthritis and Rheumatism</i> , 1999, 42, 1635-1643.	6.7	195
337	Elevated interleukin-6 in schizophrenia. <i>Psychiatry Research</i> , 1999, 87, 129-136.	1.7	77
338	IL-6 synthesis by rheumatoid synoviocytes is autonomously upregulated at the transcriptional level. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 103, S437-S444.	1.5	21
339	Anti-interleukin 6 receptor antibody treatment in rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 21i-27.	0.5	175
340	Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 175-183.	6.7	218
341	Interferon- β synergistically enhances induction of interleukin-6 by double stranded RNA in HeLa cells. <i>FEBS Journal</i> , 2000, 267, 2768-2777.	0.2	17
342	Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. <i>Immunopharmacology</i> , 2000, 47, 35-44.	2.0	91
343	Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery. <i>Gene Therapy</i> , 2000, 7, 967-977.	2.3	67
344	Selective cyclooxygenase-2 (COX-2) inhibitors reduce anti-Mycobacterium antibodies in adjuvant arthritic rats. <i>Immunopharmacology</i> , 2000, 46, 71-77.	2.0	15
345	Screening of an oligopeptide antagonist for interleukin-6 from a random phage library. <i>Biotechnology Letters</i> , 2000, 22, 1015-1020.	1.1	4
346	The anti-rheumatic effect of multiple synovectomy in patients with refractory rheumatoid arthritis. <i>International Orthopaedics</i> , 2000, 24, 242-245.	0.9	21
347	Unregulated inflammation shortens human functional longevity. <i>Inflammation Research</i> , 2000, 49, 561-570.	1.6	81
348	Kaposi sarcoma is a therapeutic target for vitamin D3receptor agonist. <i>Blood</i> , 2000, 96, 3188-3194.	0.6	45
349	gp130-mediated signalling as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2000, 4, 459-479.	1.0	2
350	Anti-CagA Immunoglobulin G Responses Correlate with Interleukin-8 Induction in Human Gastric Mucosal Biopsy Culture. <i>Vaccine Journal</i> , 2000, 7, 803-809.	2.6	20
351	IL-6 inhibits the proliferation of fibroblastic synovial cells from rheumatoid arthritis patients in the presence of soluble IL-6 receptor. <i>International Immunology</i> , 2000, 12, 187-193.	1.8	47

#	ARTICLE	IF	CITATIONS
352	A case of rheumatoid pericarditis with high concentrations of interleukin-6 in pericardial fluid. <i>British Heart Journal</i> , 2000, 83, 711-712.	2.2	17
353	Murine Oncostatin M Stimulates Mouse Synovial Fibroblasts in Vitro and Induces Inflammation and Destruction in Mouse Joints in Vivo. <i>American Journal of Pathology</i> , 2000, 157, 1187-1196.	1.9	97
354	Characterisation of monoclonal antibodies to ovine interleukin-6 and the development of a sensitive capture ELISA. <i>Veterinary Immunology and Immunopathology</i> , 2000, 73, 155-165.	0.5	30
355	Cooperative Influence of Genetic Polymorphisms on Interleukin 6 Transcriptional Regulation. <i>Journal of Biological Chemistry</i> , 2000, 275, 18138-18144.	1.6	689
356	Overexpression of Interleukin-6 Aggravates Viral Myocarditis: Impaired Increase in Tumor Necrosis Factor- α . <i>Journal of Molecular and Cellular Cardiology</i> , 2001, 33, 1627-1635.	0.9	78
357	Humanized Antibody to Human Interleukin-6 Receptor Inhibits the Development of Collagen Arthritis in Cynomolgus Monkeys. <i>Clinical Immunology</i> , 2001, 98, 319-326.	1.4	86
358	Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. <i>Bone</i> , 2001, 28, 634-640.	1.4	40
359	Immunology and immunopathology of the male genital tract: Control and impairment of immune privilege in the testis and in semen. <i>Human Reproduction Update</i> , 2001, 7, 444-449.	5.2	114
360	Triptolide, a novel diterpenoid triepoxide from <i>Tripterygium wilfordii</i> Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts. <i>Arthritis and Rheumatism</i> , 2001, 44, 2193-2200.	6.7	89
361	IL-6-Like Cytokines and Cancer Cachexia: Consequences of Chronic Inflammation. <i>Immunologic Research</i> , 2001, 23, 41-58.	1.3	91
362	Quantitative Analysis of Interleukin-6 in Vitreous from Patients with Proliferative Vitreoretinal Diseases. <i>Japanese Journal of Ophthalmology</i> , 2001, 45, 40-45.	0.9	24
363	Enhanced signal transduction by a directly fused protein of interleukin-6 and its receptor. <i>Journal of Bioscience and Bioengineering</i> , 2001, 91, 299-304.	1.1	5
364	Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. <i>Rheumatology</i> , 2001, 40, 673-682.	0.9	50
365	Noninflammatory Chronic Pelvic Pain Syndrome: Immunological Study in Blood, Ejaculate and Prostate Tissue. <i>European Urology</i> , 2001, 39, 72-78.	0.9	86
366	A prospective study of renal disease in patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 327-331.	0.5	42
367	A Point Mutation of Tyr-759 in Interleukin 6 Family Cytokine Receptor Subunit gp130 Causes Autoimmune Arthritis. <i>Journal of Experimental Medicine</i> , 2002, 196, 979-990.	4.2	205
368	Characterization of an Antagonist Interleukin-6 Dimer by Stable Isotope Labeling, Cross-linking, and Mass Spectrometry. <i>Journal of Biological Chemistry</i> , 2002, 277, 46487-46492.	1.6	103
369	Effect of Tonsillectomy on Serum Concentrations of Interleukins and TNF- α in Patients with Chronic Tonsillitis. <i>Orl</i> , 2002, 64, 254-256.	0.6	12

#	ARTICLE	IF	CITATIONS
370	ABSENCE OF ENDOGENOUS INTERLEUKIN-6 ENHANCES THE INFLAMMATORY RESPONSE DURING ACUTE PANCREATITIS INDUCED BY CERULEIN IN MICE. <i>Cytokine</i> , 2002, 18, 274-285.	1.4	47
371	ANTI-INTERLEUKIN 6 (IL-6) RECEPTOR ANTIBODY SUPPRESSES CASTLEMAN'S DISEASE LIKE SYMPTOMS EMERGED IN IL-6 TRANSGENIC MICE. <i>Cytokine</i> , 2002, 20, 304-311.	1.4	118
372	The paradigm of IL-6: from basic science to medicine. <i>Arthritis Research</i> , 2002, 4, S233.	2.0	449
373	IL-6 in autoimmune disease and chronic inflammatory proliferative disease. <i>Cytokine and Growth Factor Reviews</i> , 2002, 13, 357-368.	3.2	693
374	Importance of proinflammatory cytokines in synovial fluid from 121 joints with temporomandibular disorders. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2002, 40, 418-423.	0.4	135
375	The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2002, 1592, 323-343.	1.9	178
376	Secretory phospholipases A2 induce cytokine release from blood and synovial fluid monocytes. <i>European Journal of Immunology</i> , 2002, 32, 67-76.	1.6	59
377	Bacterial fimbriae activate human peripheral blood monocytes utilizing TLR2, CD14 and CD11a/CD18 as cellular receptors. <i>European Journal of Immunology</i> , 2002, 32, 2543-2550.	1.6	92
378	CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 2330-2338.	6.7	56
379	Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 3143-3150.	6.7	496
380	Evaluation of tissue factor antigen level in human seminal plasma. <i>Urological Research</i> , 2002, 30, 317-320.	1.5	9
381	Effect of IL-1ra on human dental pulp cells and pulpal inflammation. <i>International Endodontic Journal</i> , 2002, 35, 807-811.	2.3	16
382	Characterization of anti-mouse interleukin-6 receptor antibody. <i>Immunology Letters</i> , 2002, 84, 231-240.	1.1	94
384	IL-6 signal transduction and its physiological roles: the signal orchestration model. , 2003, 149, 1-38.		457
385	Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. <i>Biochemical Pharmacology</i> , 2003, 65, 2065-2071.	2.0	259
386	Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1521-1529.	6.7	359
387	Polymorphism at position $\hat{\sim}$ 174 of IL-6 gene is associated with susceptibility to chronic periodontitis in a Caucasian Brazilian population. <i>Journal of Clinical Periodontology</i> , 2003, 30, 438-442.	2.3	124
388	The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. <i>Immunological Reviews</i> , 2003, 194, 29-38.	2.8	241

#	ARTICLE	IF	CITATIONS
389	Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung. <i>Journal of Pathology</i> , 2003, 200, 82-87.	2.1	59
390	Immunological alterations in the ejaculate of chronic prostatitis patients: clues for autoimmunity. <i>Andrologia</i> , 2003, 35, 294-299.	1.0	32
391	Interleukin-6 (IL-6). , 2003, , 281-304.		11
392	Autoimmunity and cytokines Pathogenesis and therapy. , 2003, , 1189-1211.		2
394	Salivary and serum immunoglobulin levels in cats with chronic gingivostomatitis. <i>Veterinary Record</i> , 2003, 152, 125-129.	0.2	34
395	Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 68ii-69.	0.5	11
396	JAK/STAT but Not ERK1/ERK2 Pathway Mediates Interleukin (IL)-6/Soluble IL-6R Down-regulation of Type II Collagen, Aggrecan Core, and Link Protein Transcription in Articular Chondrocytes. <i>Journal of Biological Chemistry</i> , 2003, 278, 2903-2912.	1.6	166
397	Role of Monocytes in Atherogenesis. <i>Physiological Reviews</i> , 2003, 83, 1069-1112.	13.1	355
398	Expression of Interleukin 6 and Its Receptor in Human Gastric and Colorectal Cancers. <i>Journal of International Medical Research</i> , 2003, 31, 69-75.	0.4	38
399	Analysis of Nitrite and Nitrate in the Study of Inflammation. , 2003, 225, 305-320.		9
400	The levels of leukemia inhibitory factor in synovial tissues of patients with rheumatoid arthritis: inflammation and other proinflammatory cytokines. <i>Modern Rheumatology</i> , 2003, 13, 121-128.	0.9	6
401	Cytokines during the pathogenesis of bronchiolitis obliterans syndrome. <i>Current Opinion in Organ Transplantation</i> , 2003, 8, 228-238.	0.8	1
402	Short-Term Biological Effects of a New and Less Acidic Fluid for Peritoneal Dialysis. <i>Blood Purification</i> , 2003, 21, 287-293.	0.9	4
403	Comparison of the activities of multinucleated bone-resorbing giant cells derived from CD14-positive cells in the synovial fluids of rheumatoid arthritis and osteoarthritis patients. <i>British Journal of Rheumatology</i> , 2004, 43, 435-441.	2.5	23
404	Expression of interleukin-6 in human craniopharyngiomas: a possible inducer of tumor-associated inflammation.. <i>International Journal of Molecular Medicine</i> , 2004, 14, 505.	1.8	18
405	The point mutation of tyrosine 759 of the IL-6 family cytokine receptor gp130 synergizes with HTLV-1 pX in promoting rheumatoid arthritis-like arthritis. <i>International Immunology</i> , 2004, 16, 455-465.	1.8	18
407	The differential effects of IL-1 and TNF- α on proinflammatory cytokine and matrix metalloproteinase expression in human chondrosarcoma cells. <i>Inflammation Research</i> , 2004, 53, 377-89.	1.6	65
408	Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 1761-1769.	6.7	751

#	ARTICLE	IF	CITATIONS
409	Royal Jelly Inhibits the Production of Proinflammatory Cytokines by Activated Macrophages. <i>Bioscience, Biotechnology and Biochemistry</i> , 2004, 68, 138-145.	0.6	206
410	Clinical experience with inhibition of interleukin-6. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 405-415.	0.8	33
411	Inhibition of IL-6 for the treatment of inflammatory diseases. <i>Current Opinion in Pharmacology</i> , 2004, 4, 386-386.	1.7	0
412	Inhibition of IL-6 for the treatment of inflammatory diseases. <i>Current Opinion in Pharmacology</i> , 2004, 4, 386-391.	1.7	172
413	Activation of formyl peptide receptor-like 1 by WKYMVm induces serine phosphorylation of STAT3, which inhibits its tyrosine phosphorylation and nuclear translocation induced by hydrogen peroxide. <i>Life Sciences</i> , 2004, 75, 2217-2232.	2.0	11
414	The blockade of interleukin-6 receptor as a therapeutic strategy for chronic inflammatory diseases. <i>Therapy: Open Access in Clinical Medicine</i> , 2004, 1, 267-275.	0.2	0
415	IL-6: From Laboratory to Bedside. <i>Clinical Reviews in Allergy and Immunology</i> , 2005, 28, 177-186.	2.9	68
416	Clinical Studies in Patients With Castleman's Disease, Crohn's Disease, and Rheumatoid Arthritis in Japan. <i>Clinical Reviews in Allergy and Immunology</i> , 2005, 28, 221-230.	2.9	31
417	Effect of genetic variability on the inflammatory response to periodontal infection. <i>Journal of Clinical Periodontology</i> , 2005, 32, 72-86.	2.3	92
418	Role of the neutrophil in adult respiratory distress syndrome. <i>British Journal of Surgery</i> , 2005, 80, 10-17.	0.1	229
419	Cytokine signal regulation and autoimmune disorders. <i>Autoimmunity</i> , 2005, 38, 359-367.	1.2	27
420	INTERLEUKIN-6: From Basic Science to Medicine—40 Years in Immunology. <i>Annual Review of Immunology</i> , 2005, 23, 1-21.	9.5	882
421	The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 683-690.	1.4	78
422	Neuropeptide substance P stimulates the formation of osteoclasts via synovial fibroblastic cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 327, 756-764.	1.0	36
423	Regulatory T cells in rheumatoid arthritis. <i>Arthritis Research</i> , 2005, 7, 93.	2.0	76
424	Interleukin-6: discovery of a pleiotropic cytokine. <i>Arthritis Research and Therapy</i> , 2006, 8, S2.	1.6	396
425	The Importance of T Cell Interactions with Macrophages in Rheumatoid Cytokine Production. , 2006, 305, 177-194.		28
426	Does DHEAS Restore Immune Competence in Aged Animals through Its Capacity to Function as a Natural Modulator of Peroxisome Activities? <i>Annals of the New York Academy of Sciences</i> , 1995, 774, 200-216.	1.8	24

#	ARTICLE	IF	CITATIONS
427	Role of Th1 and Th2 Cells in Autoimmunity. , 2006, , 83-101.		1
428	Interleukin-6 in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2006, 18, 277-281.	2.0	152
429	Updating interleukin-6 classic- and trans-signaling. <i>Signal Transduction</i> , 2006, 6, 240-259.	0.7	46
430	Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane. <i>Rheumatology International</i> , 2006, 26, 1096-1100.	1.5	29
431	Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. <i>Arthritis and Rheumatism</i> , 2006, 54, 2817-2829.	6.7	729
432	Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2006, 6, 373-381.	0.6	36
433	Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7-dependent homeostatic proliferation of CD4+ T cells. <i>Journal of Experimental Medicine</i> , 2006, 203, 1459-1470.	4.2	157
434	Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1162-1167.	0.5	674
435	IL-6 Contributes to the Expression of RAGs in Human Mature B Cells. <i>Journal of Immunology</i> , 2007, 179, 6790-6798.	0.4	33
436	Clinical Relevance of Cytokines and Inflammatory Molecules in Rheumatoid Vasculitis. <i>Current Rheumatology Reviews</i> , 2007, 3, 309-316.	0.4	0
437	Recent Advances in Immunopathophysiology of Interleukin-6: An Innovative Therapeutic Drug, Tocilizumab (Recombinant Humanized Anti-human Interleukin-6 Receptor Antibody), Unveils The Mysterious Etiology of Immune-Mediated Inflammatory Diseases. <i>Biological and Pharmaceutical Bulletin</i> , 2007, 30, 2001-2006.	0.6	95
438	Update on cytokines in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2007, 19, 296-301.	2.0	76
439	Interleukin-6 Expression after Infectious Bronchitis Virus Infection in Chickens. <i>Viral Immunology</i> , 2007, 20, 479-486.	0.6	30
440	Essential Role of IL-6 Signaling Pathway in Keloid Pathogenesis. <i>Journal of Nippon Medical School</i> , 2007, 74, 11-22.	0.3	57
441	Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: An inflammatory mechanism of joint pain. <i>Arthritis and Rheumatism</i> , 2007, 56, 351-359.	6.7	217
442	Peripheral expression of RAG in human B lymphocytes in normal and pathological conditions is dependent on interleukin-6. <i>Autoimmunity Reviews</i> , 2007, 6, 415-420.	2.5	14
443	Triptolide, a diterpenoid triepoxide, suppresses inflammation and cartilage destruction in collagen-induced arthritis mice. <i>Biochemical Pharmacology</i> , 2007, 73, 136-146.	2.0	102
444	B-cell involvement in the pathogenesis of RA is there a contribution of the sympathetic nervous system?. <i>Immunologic Research</i> , 2008, 40, 148-163.	1.3	4

#	ARTICLE	IF	CITATIONS
445	The role of IL-6 in the pathogenesis of periodontal disease. <i>Oral Diseases</i> , 1998, 4, 43-47.	1.5	141
446	Biologic treatments for systemic rheumatic diseases. <i>Oral Diseases</i> , 2008, 14, 206-216.	1.5	20
447	Analysis of immunoglobulins secreted by hybridomas derived from rheumatoid synovia. <i>Clinical and Experimental Immunology</i> , 2008, 80, 366-372.	1.1	23
448	Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures. <i>Clinical and Experimental Immunology</i> , 2008, 81, 278-285.	1.1	83
449	Sequential measurement of the murine acute-phase protein serum amyloid P component (SAP) as an indicator of graft-versus-host disease following allogeneic bone marrow transplantation in mice. <i>Clinical and Experimental Immunology</i> , 2008, 81, 329-333.	1.1	4
450	Quantification of cross-reactive idiotype-positive rheumatoid factor produced in autoimmune rheumatic diseases. An indicator of clonality and B cell proliferative mechanisms. <i>Clinical and Experimental Immunology</i> , 2008, 85, 20-27.	1.1	19
451	Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumour necrosis factor-alpha. <i>Clinical and Experimental Immunology</i> , 2008, 86, 79-86.	1.1	45
452	<i>In situ</i> hybridization of IL-6 in rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2008, 87, 183-189.	1.1	77
453	IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2. <i>Clinical and Experimental Immunology</i> , 2008, 88, 207-212.	1.1	14
454	Agalactosyl IgG in pristane-induced arthritis. Pregnancy affects the incidence and severity of arthritis and the glycosylation status of IgG. <i>Clinical and Experimental Immunology</i> , 2008, 89, 434-438.	1.1	36
455	Macrophage depletion decreases IgG anti-DNA in cultures from (NZB × NZW)F1 spleen cells by eliminating the main source of IL-6. <i>Clinical and Experimental Immunology</i> , 2008, 91, 220-225.	1.1	30
456	Cytokines and autoimmunity. <i>Clinical and Experimental Immunology</i> , 2008, 96, 1-7.	1.1	38
457	Role of cytokines in experimental arthritis. <i>Clinical and Experimental Immunology</i> , 2008, 97, 1-3.	1.1	24
458	Induction of autoimmune disease by graft-versus-host reaction across MHC class II difference: modification of the lesions in IL-6 transgenic mice. <i>Clinical and Experimental Immunology</i> , 2008, 95, 525-529.	1.1	16
459	Expression of endogenous retroviruses, ERV3 and ERV1, in synovial tissues from patients with rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2008, 99, 338-344.	1.1	32
460	Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. <i>Experimental and Molecular Pathology</i> , 2008, 84, 262-270.	0.9	31
461	Immune-mediated pathways in chronic inflammatory arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 221-238.	1.4	39
462	Effects of angiotensin II blockade on the development of autoimmune thyroiditis in nonobese diabetic mice. <i>Clinical Immunology</i> , 2008, 126, 97-103.	1.4	6

#	ARTICLE	IF	CITATIONS
463	IL-6/BSF2 in Normal and Abnormal Regulation of Immune Responses. Annals of the New York Academy of Sciences, 1989, 557, 466-477.	1.8	24
464	Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. International Immunopharmacology, 2008, 8, 1595-1601.	1.7	40
465	Bestatin, an inhibitor for aminopeptidases, modulates the production of cytokines and chemokines by activated monocytes and macrophages. Cytokine, 2008, 44, 386-391.	1.4	27
466	pH-Dependent, Stereoselective Dimerization of Sinomenine. Organic Letters, 2008, 10, 3879-3882.	2.4	17
467	The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 2008, 8, 669-681.	1.4	59
468	p38 β Stabilizes Interleukin-6 mRNA via Multiple AU-rich Elements. Journal of Biological Chemistry, 2008, 283, 1778-1785.	1.6	65
469	CLONING OF HUMAN INTERLEUKIN-10 GENE AND TRANSGENE EXPRESSION IN RABBIT SYNOVIAL CELLS IN VITRO. Journal of Musculoskeletal Research, 2008, 11, 1-7.	0.1	2
470	Evidence that cytokines play a role in rheumatoid arthritis. Journal of Clinical Investigation, 2008, 118, 3537-3545.	3.9	902
471	At the horizon of innovative therapy in rheumatology: new biologic agents. Current Opinion in Rheumatology, 2008, 20, 269-275.	2.0	32
472	Suppressing Effect of Low-Dose Gamma-Ray Irradiation on Collagen-Induced Arthritis. Journal of Radiation Research, 2008, 49, 381-389.	0.8	57
473	Critical Involvement of Cytokines and Chemokines in the Pathogenesis of Rheumatoid Vasculitis. Clinical Medicine: Arthritis and Musculoskeletal Disorders, 2008, 1, CMAMD.S534.	0.0	0
475	Pharmacotherapy Options in Rheumatoid Arthritis: Focus on Tocilizumab, a Recombinant Humanized Anti-Interleukin-6 Receptor Antibody. Clinical Medicine Therapeutics, 2009, 1, CMT.S2048.	0.1	0
476	Effects of interleukin-6 blockade on the development of autoimmune thyroiditis in nonobese diabetic mice. Autoimmunity, 2009, 42, 228-234.	1.2	3
477	IL-27 Abrogates Receptor Activator of NF- κ B Ligand-Mediated Osteoclastogenesis of Human Granulocyte-Macrophage Colony-Forming Unit Cells through STAT1-Dependent Inhibition of c-Fos. Journal of Immunology, 2009, 183, 2397-2406.	0.4	66
478	Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice. BMC Musculoskeletal Disorders, 2009, 10, 23.	0.8	15
479	Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. Journal of Bone and Mineral Research, 1996, 11, 88-95.	3.1	465
480	Effects of interleukin-6 on cellular function in UMR-106 osteoblastlike cells. Journal of Bone and Mineral Research, 1991, 6, 133-139.	3.1	42
481	Human osteoblastlike cells do not respond to interleukin-6. Journal of Bone and Mineral Research, 1991, 6, 141-148.	3.1	60

#	ARTICLE	IF	CITATIONS
482	Interleukin 6 in the Physiopathology of Rheumatoid Arthritis. <i>Reumatología Clínica (English Edition)</i> , 2009, 5, 34-39.	0.2	10
483	Anti-Arthritic Activity of Hydroalcoholic Extract of Flowers of <i>Moringa oleifera</i> Lam. in Wistar Rats. <i>Journal of Herbs, Spices and Medicinal Plants</i> , 2009, 15, 149-163.	0.5	12
485	Anti-Cytokine Therapeutics: History and Update. <i>Current Pharmaceutical Design</i> , 2009, 15, 1998-2025.	0.9	32
486	Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2010, 86, 717-730.	1.6	137
487	The Inhibitory Effect of Interleukin-10 on Mouse Osteoclast Formation Involves Novel Tyrosine-Phosphorylated Proteins. <i>Journal of Bone and Mineral Research</i> , 2010, 15, 911-918.	3.1	73
488	Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. <i>Rheumatology International</i> , 2010, 30, 917-923.	1.5	63
489	Interleukin-6: From identification of the cytokine to development of targeted treatments. <i>Joint Bone Spine</i> , 2010, 77, 532-536.	0.8	67
490	Low levels of interleukin-4 and high levels of transforming growth factor β^2 in rheumatoid synovitis. <i>Arthritis and Rheumatism</i> , 1990, 33, 1180-1187.	6.7	154
491	Interleukine-6 : de la découverte de la cytokine au développement d'un traitement ciblé. <i>Revue Du Rhumatisme (Edition Française)</i> , 2010, 77, S16-S22.	0.0	1
492	Proviral integration site 2 is required for interleukin-6 expression induced by interleukin-1, tumour necrosis factor- α and lipopolysaccharide. <i>Immunology</i> , 2010, 131, 174-182.	2.0	11
493	Averting inflammation by targeting the cytokine environment. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 703-718.	21.5	222
494	Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. <i>Therapeutics and Clinical Risk Management</i> , 2010, 6, 143.	0.9	26
495	Neurotrophins Regulate Bone Marrow Stromal Cell IL-6 Expression through the MAPK Pathway. <i>PLoS ONE</i> , 2010, 5, e9690.	1.1	48
496	Tocilizumab for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 843-854.	1.3	70
497	The study of cytokines by Japanese researchers: a historical perspective. <i>International Immunology</i> , 2010, 22, 341-345.	1.8	1
498	Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 385-404.	0.8	169
499	Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 397-403.e10.	1.5	142
500	Disaccharide derived from chondroitin sulfate A suppressed CpG-induced IL-6 secretion in macrophage-like J774.1 cells. <i>Cytokine</i> , 2010, 51, 53-59.	1.4	10

#	ARTICLE	IF	CITATIONS
501	IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. <i>Cytokine</i> , 2010, 51, 178-183.	1.4	45
502	Fibroblast-like synoviocytes in inflammatory arthritis pathology: the emerging role of cadherin-11. <i>Immunological Reviews</i> , 2010, 233, 256-266.	2.8	124
503	IL-6: from its discovery to clinical applications. <i>International Immunology</i> , 2010, 22, 347-352.	1.8	664
504	Dual role of interleukin-17 in pannus growth and osteoclastogenesis in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R14.	1.6	29
505	A Four-Step Model for the IL-6 Amplifier, a Regulator of Chronic Inflammations in Tissue-Specific MHC Class II-Associated Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2011, 2, 22.	2.2	42
506	IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab. <i>Current Rheumatology Reviews</i> , 2011, 7, 288-300.	0.4	1
507	Intercellular adhesion molecule-1 on synovial cells attenuated interleukin-6-induced inhibition of osteoclastogenesis induced by receptor activator for nuclear factor κ B ligand. <i>Clinical and Experimental Immunology</i> , 2010, 163, 88-95.	1.1	16
508	Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. <i>FEBS Letters</i> , 2011, 585, 3699-3709.	1.3	123
509	Immune modulation of rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 873-889.	1.4	7
510	Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis. <i>Molecular Biology Reports</i> , 2011, 38, 4225-4230.	1.0	25
511	Lung transplantation: infection, inflammation, and the microbiome. <i>Seminars in Immunopathology</i> , 2011, 33, 135-156.	2.8	51
512	Genetic Evidence for an Essential Role of Neuronally Expressed IL-6 Signal Transducer gp130 in the Induction and Maintenance of Experimentally Induced Mechanical Hypersensitivity <i>in vivo</i> and <i>in vitro</i> . <i>Molecular Pain</i> , 2011, 7, 1744-8069-7-73.	1.0	37
513	Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for the treatment of autoimmune disorders. <i>Drug Development Research</i> , 2011, 72, 717-732.	1.4	1
514	Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2022-2028.	0.5	143
515	Tocilizumab for the Treatment of Adults with Moderate to Severe Rheumatoid Arthritis. <i>Clinical Medicine Reviews in Therapeutics</i> , 0, 3, 143-154.	0.4	0
516	IL-6 <i>Trans</i> -Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3. <i>Journal of Immunology</i> , 2011, 186, 1199-1208.	0.4	250
517	IL-6/IL-6 receptor system and its role in physiological and pathological conditions. <i>Clinical Science</i> , 2012, 122, 143-159.	1.8	637
518	Immunotherapeutic implication of IL-6 blockade. <i>Immunotherapy</i> , 2012, 4, 87-105.	1.0	35

#	ARTICLE	IF	CITATIONS
519	LPS hypersensitivity of gp130 mutant mice is independent of elevated haemopoietic TLR4 signaling. <i>Immunology and Cell Biology</i> , 2012, 90, 559-563.	1.0	15
520	Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-14.	0.9	40
521	The role of B cells in bone turnover in rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 167-177.	0.3	0
522	IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 2306.	3.0	148
523	Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1243-1248.	0.5	74
524	The role of tocilizumab in the management of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1277-1289.	1.4	26
525	Interleukin-6, its role in fibrosing conditions. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 99-107.	3.2	73
526	Differential regulation of intracellular factors mediating cell cycle, DNA repair and inflammation following exposure to silver nanoparticles in human cells. <i>Genome Integrity</i> , 2012, 3, 2.	1.0	121
527	Inducible MicroRNA-223 Down-Regulation Promotes TLR-Triggered IL-6 and IL-1 β Production in Macrophages by Targeting STAT3. <i>PLoS ONE</i> , 2012, 7, e42971.	1.1	218
528	The Pathological and Physiological Roles of IL-6 Amplifier Activation. <i>International Journal of Biological Sciences</i> , 2012, 8, 1267-1280.	2.6	55
529	Cross-Regulation of JAK-STAT Signaling: Implications for Approaches to Combat Chronic Inflammatory Diseases and Cancers. , 0, , .		0
530	The Stress Response and Its Functional Implications in the Immune Response After Surgery in Patients with Chronic Inflammation Undergoing Arthroplasty. , 2012, , .		1
531	Therapeutic Targeting of the Interleukin-6 Receptor. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 199-219.	4.2	240
532	Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse. <i>European Journal of Pharmacology</i> , 2012, 678, 55-60.	1.7	32
533	Interleukin-6 in oral diseases: a review. <i>Oral Diseases</i> , 2012, 18, 236-243.	1.5	126
534	The role of IL-6 in bone marrow (BM)-derived mesenchymal stem cells (MSCs) proliferation and chondrogenesis. <i>Cell and Tissue Banking</i> , 2013, 14, 699-706.	0.5	23
535	Tocilizumab in Pediatric Rheumatology: The Clinical Experience. <i>Current Rheumatology Reports</i> , 2013, 15, 338.	2.1	4
536	Human Umbilical Cord Mesenchymal Stem Cell Therapy for Patients with Active Rheumatoid Arthritis: Safety and Efficacy. <i>Stem Cells and Development</i> , 2013, 22, 3192-3202.	1.1	202

#	ARTICLE	IF	CITATIONS
537	IL-32 with potential insights into rheumatoid arthritis. <i>Clinical Immunology</i> , 2013, 147, 89-94.	1.4	31
538	IL-33 in rheumatoid arthritis: Potential role in pathogenesis and therapy. <i>Human Immunology</i> , 2013, 74, 1057-1060.	1.2	41
539	Aryl hydrocarbon receptor and experimental autoimmune arthritis. <i>Seminars in Immunopathology</i> , 2013, 35, 637-644.	2.8	51
540	Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 537-548.	0.3	17
541	Recipient IL-6-572C/G genotype is associated with reduced incidence of acute rejection following liver transplantation. <i>Journal of International Medical Research</i> , 2013, 41, 356-364.	0.4	13
542	Possible Role for Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia. <i>Journal of Clinical Oncology</i> , 2013, 31, e69-e72.	0.8	102
543	Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. <i>Patient Preference and Adherence</i> , 2013, 7, 653.	0.8	21
544	Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases. <i>Inflammation and Regeneration</i> , 2013, 33, 054-065.	1.5	13
545	Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e61835.	1.1	184
546	The -174G/C and -572G/C Interleukin 6 Promoter Gene Polymorphisms in Mexican Patients with Rheumatoid Arthritis: A Case-Control Study. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-5.	3.3	19
547	Primary pathologic role of interleukin-6 in rheumatoid arthritis. <i>Italian Journal of Medicine</i> , 2013, , 40-46.	0.2	2
548	Tocilizumab in the treatment of rheumatoid arthritis and beyond. <i>Drug Design, Development and Therapy</i> , 2014, 8, 349.	2.0	70
549	Interleukin 6 and Rheumatoid Arthritis. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	149
550	History and Perspectives of Research in Bone Marrow Stromal Cell Antigen-1 (BST-1)/CD157: A Relative of ADP-Ribosyl Cyclase CD38. <i>Messenger (Los Angeles, Calif: Print)</i> , 2014, 3, 15-20.	0.3	5
551	Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept) therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1616-1625.	0.5	135
552	Matrix-assisted refolding and purification of placenta-derived recombinant human interleukin-6 produced in <i>Escherichia coli</i> . <i>Biotechnology and Applied Biochemistry</i> , 2014, 61, 541-548.	1.4	5
553	Th17 Differentiation and Their Pro-inflammation Function. <i>Advances in Experimental Medicine and Biology</i> , 2014, 841, 99-151.	0.8	65
554	Revisiting the 1986 Molecular Cloning of Interleukin 6. <i>Frontiers in Immunology</i> , 2014, 5, 456.	2.2	32

#	ARTICLE	IF	CITATIONS
555	The role of IL-6 on apical periodontitis: a systematic review. <i>International Endodontic Journal</i> , 2014, 47, 615-621.	2.3	78
556	Rheumatoid Arthritis Bone Fragility Is Associated With Upregulation of IL17 and DKK1 Gene Expression. <i>Clinical Reviews in Allergy and Immunology</i> , 2014, 47, 38-45.	2.9	30
557	A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. <i>Seminars in Immunology</i> , 2014, 26, 88-96.	2.7	144
558	Interleukin-6 signal transduction and its role in hepatic lipid metabolic disorders. <i>Cytokine</i> , 2014, 66, 133-142.	1.4	37
559	T Helper Cell Differentiation and Their Function. <i>Advances in Experimental Medicine and Biology</i> , 2014, , ,	0.8	7
560	IL-6 in Inflammation, Immunity, and Disease. <i>Cold Spring Harbor Perspectives in Biology</i> , 2014, 6, a016295-a016295.	2.3	2,943
561	IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. <i>Journal of Bone and Mineral Metabolism</i> , 2014, 32, 378-392.	1.3	156
562	Interleukin-6 is linked to longitudinal rates of cortical thinning in aging. <i>Translational Neuroscience</i> , 2014, 5, 1-7.	0.7	31
563	Aberrant histone acetylation contributes to elevated interleukin-6 production in rheumatoid arthritis synovial fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2014, 444, 682-686.	1.0	98
565	Histone Methylation and STAT3 Differentially Regulate Interleukin-6-Induced Matrix Metalloproteinase Gene Activation in Rheumatoid Arthritis Synovial Fibroblasts. <i>Arthritis and Rheumatology</i> , 2016, 68, 1111-1123.	2.9	70
566	Targeting interleukin-6 for noninfectious uveitis. <i>Clinical Ophthalmology</i> , 2015, 9, 1697.	0.9	52
567	Discovery and Development of Anti-TNF Therapy. , 2015, , 541-547.		0
568	Molecular aspects in inflammatory events of temporomandibular joint: Microarray-based identification of mediators. <i>Japanese Dental Science Review</i> , 2015, 51, 10-24.	2.0	4
569	Preventive effects of CTLA4lg-overexpressing adipose tissue-derived mesenchymal stromal cells in rheumatoid arthritis. <i>Cytotherapy</i> , 2015, 17, 271-282.	0.3	8
570	Anti-Interleukin-6 Receptor Antibody Therapy Against Autoimmune Inflammatory Diseases. , 2015, , 515-525.		0
571	The varying faces of IL-6: From cardiac protection to cardiac failure. <i>Cytokine</i> , 2015, 74, 62-68.	1.4	248
572	Rheumatoid arthritis: Biological therapy other than anti-TNF. <i>International Immunopharmacology</i> , 2015, 27, 185-188.	1.7	32
573	Animal models of rheumatoid arthritis: How informative are they?. <i>European Journal of Pharmacology</i> , 2015, 759, 278-286.	1.7	76

#	ARTICLE	IF	CITATIONS
574	Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis. <i>Therapeutic Delivery</i> , 2015, 6, 283-295.	1.2	11
575	Inflammation induced loss of skeletal muscle. <i>Bone</i> , 2015, 80, 131-142.	1.4	205
576	Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 307-316.	1.5	32
577	Zinc homeostasis and immunosenescence. <i>Journal of Trace Elements in Medicine and Biology</i> , 2015, 29, 24-30.	1.5	60
578	Salivary markers of inflammation in response to acute stress. <i>Brain, Behavior, and Immunity</i> , 2015, 44, 253-269.	2.0	197
579	IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer. <i>Oncology Reports</i> , 2016, 35, 1787-1795.	1.2	86
580	Equol suppresses inflammatory response and bone erosion due to rheumatoid arthritis in mice. <i>Journal of Nutritional Biochemistry</i> , 2016, 32, 101-106.	1.9	27
581	Preconditioning of physiological cyclic stretch attenuated HMGB1 expression in pathologically mechanical stretch-activated A549 cells and ventilator-induced lung injury rats through inhibition of IL-6/STAT3/SOCS3. <i>International Immunopharmacology</i> , 2016, 31, 66-73.	1.7	11
582	Chlorogenic acid induces apoptosis to inhibit inflammatory proliferation of IL-6-induced fibroblast-like synoviocytes through modulating the activation of JAK/STAT and NF- κ B signaling pathways. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 2054-2060.	0.8	69
583	Pain in rheumatoid arthritis: models and mechanisms. <i>Pain Management</i> , 2016, 6, 265-284.	0.7	53
584	Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis. <i>International Immunopharmacology</i> , 2016, 35, 301-306.	1.7	22
585	Levels of serum pentraxin 3, IL-6, fetuin A and insulin in patients with rheumatoid arthritis. <i>Cytokine</i> , 2016, 83, 171-175.	1.4	29
586	Cytokine gene polymorphisms and their association with cervical cancer: A North Indian study. <i>Egyptian Journal of Medical Human Genetics</i> , 2016, 17, 155-163.	0.5	19
587	Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2016, 18, 72.	2.1	10
588	Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. <i>Science Translational Medicine</i> , 2016, 8, 356ra119.	5.8	82
589	Increased expression of interleukin-6 (IL-6) gene transcript in relation to IL-6 promoter hypomethylation in gingival tissue from patients with chronic periodontitis. <i>Archives of Oral Biology</i> , 2016, 69, 89-94.	0.8	33
590	Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 10-19.	2.0	32
591	Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6. <i>AAPS Journal</i> , 2016, 18, 767-776.	2.2	27

#	ARTICLE	IF	CITATIONS
592	Interferon regulatory factor 5 in human autoimmunity and murine models of autoimmune disease. <i>Translational Research</i> , 2016, 167, 167-182.	2.2	70
593	Autocrine Loop Involving IL-6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production of Inflammatory Mediators. <i>Immunity</i> , 2017, 46, 220-232.	6.6	117
594	Gateway reflexes: A new paradigm of neuroimmune interactions. <i>Clinical and Experimental Neuroimmunology</i> , 2017, 8, 23-32.	0.5	10
595	Selected cytokine pathways in rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 2017, 39, 365-383.	2.8	236
596	The role and therapeutic targeting of IL-6 in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 535-551.	1.3	166
597	Inflammatory cytokines in normal and irreversibly inflamed pulps: A systematic review. <i>Archives of Oral Biology</i> , 2017, 82, 38-46.	0.8	44
598	Association of IL-6 -174 G>C polymorphism with the risk of SLE among south Indians: evidence from caseâ€“control study and meta-analysis. <i>Lupus</i> , 2017, 26, 1491-1501.	0.8	14
599	Identifying the association between interleukin-6 and lichen planus: A meta-analysis. <i>Biomedical Reports</i> , 2017, 6, 571-575.	0.9	8
600	Potential Involvement of the IL-6/JAK/STAT3 Pathway in the Pathogenesis of Intervertebral Disc Degeneration. <i>Spine</i> , 2017, 42, E817-E824.	1.0	37
601	A review on interleukins: The key manipulators in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2017, 27, 723-746.	0.9	16
603	Targeting interleukin-6 in autoimmune uveitis. <i>Autoimmunity Reviews</i> , 2017, 16, 1079-1089.	2.5	53
604	Expression of aryl hydrocarbon receptor, inflammatory cytokines, and incidence of rheumatoid arthritis in Vietnamese dioxin-exposed people. <i>Journal of Immunotoxicology</i> , 2017, 14, 196-203.	0.9	10
605	Effect of tryptase inhibition on joint inflammation: a pharmacological and lentivirus-mediated gene transfer study. <i>Arthritis Research and Therapy</i> , 2017, 19, 124.	1.6	15
606	IL-6 Superfamily. , 2017, , 573-586.		2
608	Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib. <i>Frontiers in Physiology</i> , 2017, 8, 775.	1.3	19
609	Anti-Inflammatory Activity of a Polymeric Proanthocyanidin from <i>Serjania schiedeana</i> . <i>Molecules</i> , 2017, 22, 863.	1.7	22
610	Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, S20-S28.	1.0	1
611	Clinical response to non-surgical periodontal treatment in patients with interleukin-6 and interleukin-10 polymorphisms. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2017, 22, 0-0.	0.7	6

#	ARTICLE	IF	CITATIONS
612	Physiology and Pathology of Autoimmune Diseases: Role of CD4+ T cells in Rheumatoid Arthritis. , 2017, , .		7
613	Physiological effects of modulating the interleukin-6 axis. <i>Rheumatology</i> , 2018, 57, ii43-ii50.	0.9	91
614	Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients. <i>Arthritis Research and Therapy</i> , 2018, 20, 42.	1.6	13
615	Interleukin (IL-6) Immunotherapy. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028456.	2.3	223
616	The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. <i>Biochemical Society Transactions</i> , 2018, 46, 1449-1462.	1.6	88
617	IL-6: a cytokine at the crossroads of autoimmunity. <i>Current Opinion in Immunology</i> , 2018, 55, 9-14.	2.4	73
618	Immunotherapeutic Approaches of Rheumatoid Arthritis and the Implication on Novel Interventions for Refractoriness. , 0, , .		0
619	Comparative study of anti-VEGF Ranibizumab and Interleukin-6 receptor antagonist Tocilizumab in Adjuvant-induced Arthritis. <i>Toxicology and Applied Pharmacology</i> , 2018, 356, 65-75.	1.3	19
620	The Relationship Between Serum Pentraxin 3 Levels and Hematological Markers in Patients With Rheumatoid Arthritis. <i>Archives of Rheumatology</i> , 2018, 33, 39-44.	0.3	8
621	Regulatory B lymphocytes: development and modulation of the host immune response during disease. <i>Immunotherapy</i> , 2019, 11, 691-704.	1.0	11
622	Paradoxical role of Breg-inducing cytokines in autoimmune diseases. <i>Journal of Translational Autoimmunity</i> , 2019, 2, 100011.	2.0	15
623	Autoantibodies and Cytokines in Pathogenesis of Rheumatoid Arthritis. , 2019, , .		0
624	Inflammatory patterns of antrochoanal polyps in the pediatric age group. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 39.	0.9	12
626	A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity. <i>Npj Genomic Medicine</i> , 2019, 4, 23.	1.7	91
627	Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. <i>Immunity</i> , 2019, 50, 812-831.	6.6	335
628	The many facets of macrophages in rheumatoid arthritis. <i>Biochemical Pharmacology</i> , 2019, 165, 152-169.	2.0	144
629	B cell checkpoints in autoimmune rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2019, 15, 303-315.	3.5	62
630	Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression.. <i>Bone Reports</i> , 2019, 11, 100228.	0.2	23

#	ARTICLE	IF	CITATIONS
631	The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. <i>Modern Rheumatology</i> , 2019, 29, 294-301.	0.9	19
632	Fibrosis and Immune Dysregulation in Systemic Sclerosis. <i>Molecular and Translational Medicine</i> , 2019, , 25-60.	0.4	0
633	A new constituent against rheumatoid arthritis from the flower buds of <i>Lonicera japonica</i> . <i>Phytochemistry Letters</i> , 2019, 29, 160-164.	0.6	3
634	The periodontal stem/progenitor cell inflammatoryâ€“regenerative cross talk: A new perspective. <i>Journal of Periodontal Research</i> , 2019, 54, 81-94.	1.4	57
635	The Cytokine Interleukin 6 (IL-6) as a Neural and Endocrine Regulator. <i>Advances in Neuroimmune Biology</i> , 2020, 7, 135-148.	0.7	0
636	The immunobiology of humanized Anti-IL6 receptor antibody: From basic research to breakthrough medicine. <i>Journal of Translational Autoimmunity</i> , 2020, 3, 100030.	2.0	6
637	IL-6 is present in beta and alpha cells in human pancreatic islets: Expression is reduced in subjects with type 1 diabetes. <i>Clinical Immunology</i> , 2020, 211, 108320.	1.4	26
638	High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab. <i>Arthritis Research and Therapy</i> , 2020, 22, 250.	1.6	17
639	Historical overview of the interleukin-6 family cytokine. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	115
640	Serum Levels of Heparin in Rheumatoid Arthritis and Its Correlation with Disease Activity and Anemia: A Meta-analysis. <i>Immunological Investigations</i> , 2021, 50, 243-258.	1.0	13
641	Infusion of HLA-matched and static magnetic field-exposed allogenic lymphocytes treating lymphocytopenia and cytokine storm syndrome: A treatment proposal for COVID-19 patients. <i>Electromagnetic Biology and Medicine</i> , 2021, 40, 11-25.	0.7	4
642	IL-6 in inflammation, autoimmunity and cancer. <i>International Immunology</i> , 2021, 33, 127-148.	1.8	500
643	Interleukin 6 in Patients with Rheumatoid Arthritis. , 0, , .		0
644	Rheumatoid arthritis: Development after the emergence of a chemokine for neutrophils in the synovium. <i>BioEssays</i> , 2021, 43, 2100119.	1.2	4
645	SCIMP is a spatiotemporal transmembrane scaffold for Erk1/2 to direct pro-inflammatory signaling in TLR-activated macrophages. <i>Cell Reports</i> , 2021, 36, 109662.	2.9	9
647	Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2021, 20, 102884.	2.5	57
648	Association of interleukin-6 promoter polymorphism with rheumatoid arthritis: a meta-analysis with trial sequential analysis. <i>Clinical Rheumatology</i> , 2022, 41, 411-419.	1.0	3
649	Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies. <i>Regenerative Therapy</i> , 2021, 18, 152-160.	1.4	11

#	ARTICLE	IF	CITATIONS
650	The Role of Interleukin 6 in Plasmacytomagenesis. Novartis Foundation Symposium, 1992, 167, 188-204.	1.2	7
651	Interleukin 6 Determination in the Detection of Microbial Invasion of the Amniotic Cavity. Novartis Foundation Symposium, 1992, 167, 205-226.	1.2	63
652	Interleukin 6: A Multifunctional Cytokine Regulating Immune Reactions and the Acute Phase Protein Response. , 1990, , 97-111.		147
653	Interleukin-6. , 1991, , 633-665.		7
654	Significance and Molecular Basis for IgG Glycosylation Changes in Rheumatoid Arthritis. Advances in Experimental Medicine and Biology, 1995, 376, 193-204.	0.8	12
655	Omega-3s and Immune/Inflammatory Responses. , 1995, , 187-248.		2
656	Interleukin-6. Handbook of Experimental Pharmacology, 1990, , 633-665.	0.9	60
657	Pathogenesis of Rheumatoid Arthritis: Cellular and Cytokine Interactions. , 1992, , 41-54.		10
658	Interleukin 6 and Its Receptor in Immune Regulation. , 1989, , 633-640.		2
659	Interleukin-6: possible implications in human diseases. Research in Clinic and Laboratory, 1989, 19, 1-10.	0.3	25
660	IL-6 Receptor. , 1990, , 219-243.		6
661	Cytokine action on B cells in disease. , 1990, , 215-251.		2
662	Autoimmune Arthropathy: Rheumatoid Synovitis. , 1992, , 363-385.		2
663	Interleukin-6. , 1998, , 87-108.		6
664	Mediators of Inflammation. , 2011, , 914-932.		2
665	Histamine enhances interleukin (IL)-1-induced IL-6 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. Journal of Biological Chemistry, 1994, 269, 9952-9956.	1.6	54
666	Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. Journal of Biological Chemistry, 1991, 266, 2647-2651.	1.6	372
667	Structure of the Rat Interleukin 6 Gene and Its Expression in Macrophage-derived Cells. Journal of Biological Chemistry, 1989, 264, 16072-16082.	1.6	177

#	ARTICLE	IF	CITATIONS
668	Immunological alterations in the ejaculate of chronic prostatitis patients: clues for autoimmunity. <i>Andrologia</i> , 2003, 35, 294-299.	1.0	5
669	<i>Mycoplasma fermentans</i> -derived high-molecular-weight material induces interleukin-6 release in cultures of murine macrophages and human monocytes. <i>Infection and Immunity</i> , 1990, 58, 1273-1280.	1.0	48
670	Involvement of interleukin-1 (IL-1), IL-6, IL-2, and IL-4 in generation of cytolytic T cells from thymocytes stimulated by a <i>Mycoplasma fermentans</i> -derived product. <i>Infection and Immunity</i> , 1991, 59, 3962-3968.	1.0	37
671	Differential Normalization of Mucosal Interleukin-8 and Interleukin-6 Activity after <i>Helicobacter pylori</i> Eradication. <i>Infection and Immunity</i> , 1998, 66, 4742-4747.	1.0	67
672	A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. <i>Journal of Virology</i> , 1996, 70, 8485-8491.	1.5	144
673	Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. <i>Molecular and Cellular Biology</i> , 1990, 10, 2327-2334.	1.1	577
674	Constitutive and Interleukin-1 (IL-1)-Inducible Factors Interact with the IL-1-Responsive Element in the IL-6 Gene. <i>Molecular and Cellular Biology</i> , 1990, 10, 2757-2764.	1.1	102
675	Serum soluble intercellular adhesion molecule-1, interleukin-8 and interleukin-6 levels in patients with Behcet's disease. <i>The Pain Clinic</i> , 2003, 15, 159-165.	0.1	1
676	The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. <i>Journal of Clinical Investigation</i> , 2002, 110, 651-658.	3.9	279
677	Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.. <i>Journal of Clinical Investigation</i> , 1989, 84, 2008-2011.	3.9	443
678	Role of lymphotoxin in expression of interleukin 6 in human fibroblasts. Stimulation and regulation.. <i>Journal of Clinical Investigation</i> , 1990, 85, 121-129.	3.9	70
679	Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.. <i>Journal of Clinical Investigation</i> , 1990, 86, 592-599.	3.9	301
680	Interleukin-6 production in posttransplant lymphoproliferative disease.. <i>Journal of Clinical Investigation</i> , 1993, 91, 2806-2814.	3.9	96
681	Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.. <i>Journal of Clinical Investigation</i> , 1994, 93, 2114-2119.	3.9	216
682	Interleukin-6 attenuates agonist-mediated calcium mobilization in murine osteoblastic cells.. <i>Journal of Clinical Investigation</i> , 1994, 93, 2340-2350.	3.9	28
683	Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.. <i>Journal of Clinical Investigation</i> , 1994, 94, 585-591.	3.9	218
684	Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides.. <i>Journal of Clinical Investigation</i> , 1995, 96, 2357-2363.	3.9	344
685	The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. <i>Journal of Clinical Investigation</i> , 2002, 110, 651-658.	3.9	157

#	ARTICLE	IF	CITATIONS
686	APC-derived cytokines and T cell polarization in autoimmune inflammation. Journal of Clinical Investigation, 2007, 117, 1119-1127.	3.9	362
687	The biology of interleukin-6. Blood, 1989, 74, 1-10.	0.6	620
688	Kaposi sarcoma is a therapeutic target for vitamin D3receptor agonist. Blood, 2000, 96, 3188-3194.	0.6	3
689	Enhanced Signal Transduction by a Directly Fused Protein of Interleukin-6 and Its Receptor.. Journal of Bioscience and Bioengineering, 2001, 91, 299-304.	1.1	4
690	Phospholipase D1 Mediates TNF α -Induced Inflammation in a Murine Model of TNF α -Induced Peritonitis. PLoS ONE, 2010, 5, e10506.	1.1	26
691	Pre- and Post-operative cytokines in patients with gallbladder stone.. Japanese Journal of Clinical Immunology, 1992, 15, 451-458.	0.0	1
693	Association of gene variants in TLR4 and IL-6 genes with Perthes disease. Srpski Arhiv Za Celokupno Lekarstvo, 2014, 142, 450-456.	0.1	18
695	Analysis of local production of inflammatory cytokines in primary biliary cirrhosis by reverse transcription-polymerase chain reaction.. Acta Hepatologica Japonica, 1992, 33, 863-871.	0.0	1
696	Cytokines, Adhesion Molecules, and Immune Deviation in Autoimmune Salivary Gland Disease. Oral Medicine & Pathology, 1996, 1, 3-10.	0.3	1
697	Recent Advances in Electrochemical and Optical Biosensors Designed for Detection of Interleukin 6. Sensors, 2020, 20, 646.	2.1	32
698	Osteoklasten: Universelle Zellen der Knochenumstrukturierung. Hefte Zur Zeitschrift Der Unfallchirurg, 2000, , 43-61.	0.0	0
699	The Possible Role of Locally Produced Cytokines in the Pathogenesis of Peritrochanteric Fractures in the Elderly. Orthopedics, 2001, 24, 763-766.	0.5	1
700	Is IL-6 a therapeutic target?. , 2004, , 89-106.		0
701	1'. The Effects of Substance P on the Synovial Fibroblastic Cells from the Human Temporomandibular Joint. The Journal of the Kyushu Dental Society, 2005, 59, 119-120.	0.0	0
702	The Effects of Substance P on the Synovial Fibroblastic Cells from the Human Temporomandibular Joint. The Journal of the Kyushu Dental Society, 2005, 59, 14-21.	0.0	0
703	Immunobiology of IL-6 α 1" Tocilizumab (humanised anti-IL-6 receptor antibody) for the treatment of rheumatoid arthritis. , 2009, , 45-57.		0
704	Cytokine spectrum of blood serum during inflammatory processes in the abdominal cavity. Fiziolohichniy Zhurnal (Kiev, Ukraine: 1994), 2010, 56, 45-48.	0.1	0
705	Biocompatibility and Gene Expression Associated with Streptococcus Infection in Myocarditis. International Journal of Genetic Engineering, 2012, 2, 1-11.	0.5	2

#	ARTICLE	IF	CITATIONS
706	Cytokine Production in Culture by Cells Isolated from the Synovial Membrane. , 1989, , 177-186.		0
707	Cytokines and rheumatoid arthritis.. Ensho, 1990, 10, 437-443.	0.0	0
708	Immune Abnormalities in the Pathogenesis of Juvenile Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 1991, 17, 843-857.	0.8	11
709	Interleukins. , 1992, , 71-91.		0
710	The role of histamine receptor in IL-6 production in human peripheral blood lymphocytes.. Ensho, 1992, 12, 269-272.	0.0	0
711	Study of Interleukin-6 Expression in Periodontitis.. Journal of Japanese Society of Periodontology, 1992, 34, 277-285.	0.1	1
712	Studies on the Production of Recombinant Human NF- κ B in Mouse L cell. , 1992, , 405-412.		0
713	Assessment of Interleukin-6 in the Progression of Periodontal Disease.. Journal of Japanese Society of Periodontology, 1992, 34, 286-300.	0.1	1
714	Effects of TA-383 on the proliferation and cytokine production of rheumatoid synovium.. Ensho, 1992, 12, 573-574.	0.0	1
715	Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin. Blood, 1992, 80, 194-202.	0.6	33
716	Interleukin 6 as a Mediator of the Systemic Inflammatory Response. , 1993, , 34-56.		0
717	Study on cytokines produced by cystic tissues in the jaw.. Nihon Koku Geka Gakkai Zasshi, 1993, 39, 353-366.	0.0	0
718	The Role of T Cells in the Immunopathogenesis of the Connective Tissue Diseases: Rheumatoid Arthritis as the Paradigm. , 1994, , 1-22.		0
719	Interleukin-6 receptor(IL-6R) dynamics in patients with rheumatoid arthritis.. Ensho, 1994, 14, 489-497.	0.0	0
720	Studies on cytokines produced by alveolar macrophages in the patients with sarcoidosis. Okayama Igakkai Zasshi, 1994, 106, 349-357.	0.0	0
721	Cytokine Antibodies and Antagonists in the Treatment of Sepsis. , 1995, , 199-224.		0
722	An Excess of IL-6 Production in the Early Muscle Stage of Trichinella spiralis Infection in Mice is Associated with Strain Susceptibility to Infection. , 1997, , 189-195.		1
723	Mechanisms of Transfer into SCID Mice Reconstituted with Tissue-infiltrating Cells from Murine Model for Sjogren's Syndrome.. Oral Medicine & Pathology, 1998, 3, 67-74.	0.3	0

#	ARTICLE	IF	CITATIONS
724	Pathogenetical and Clinical Aspects of Antisperm Immunity. , 1999, , 242-255.		1
725	The Role of Exogenous Stimulation in Pathogenesis of Autoimmune Diseases. , 1999, , 141-155.		0
726	Effect of Gamikyejakjimo-tang(jiÄwÄiguÄshÄjozhÄ«m-tÄng) ethanol extract on Rheumatoid Arthritis factors. The Korea Journal of Herbology, 2014, 29, 65-73.	0.2	4
727	DMfreeÄ®(Green Tea Extract) Inhibits IL-6 of Mycobacterium leprae Infected Mesenchymal Stem Cells. The Korean Journal of Food and Nutrition, 2015, 28, 695-701.	0.3	0
728	Influence of -174G/C IL-6 gene polymorphism on the susceptibility to rheumatoid arthritis in children and adults in the Republic Of Belarus. , 2018, 62, 608-614.	0.0	1
729	Targeting Interleukin-6 in Ocular Inflammatory Diseases. , 2019, , 95-112.		0
731	Restoration of Immunocompetence in Aging and Other Inflammatory Disease States by Dehydroepiandrosterone-3ÄSulfate, an Activator of the Peroxisome Proliferator-Activated Receptor Alpha (PPARÄ). , 0, , .		0
732	The blockade of interleukin-6 receptor as a therapeutic strategy for chronic inflammatory diseases. Therapy: Open Access in Clinical Medicine, 2004, 1, 267-275.	0.2	0
733	Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Seminars in Immunopathology, 1998, 20, 247-259.	4.0	4
738	RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO Journal, 1995, 14, 1187-97.	3.5	63
739	Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO Journal, 1991, 10, 4025-31.	3.5	604
740	A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO Journal, 1990, 9, 1897-906.	3.5	529
741	Contrasting effects of interferon-gamma and interleukin-4 on the interleukin-6 activity of stimulated human monocytes. Immunology, 1990, 71, 70-5.	2.0	68
742	Reduced galactosyltransferase mRNA levels are associated with the agalactosyl IgG found in arthritis-prone MRL-lpr/lpr strain mice. Immunology, 1994, 83, 484-8.	2.0	11
743	Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-kappaB and CBF1. American Journal of Pathology, 1998, 152, 793-803.	1.9	77
744	Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. American Journal of Pathology, 1996, 149, 1675-83.	1.9	169
745	4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis. American Journal of Pathology, 1994, 144, 244-59.	1.9	26
746	Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice. American Journal of Pathology, 1994, 145, 157-66.	1.9	59

#	ARTICLE	IF	CITATIONS
747	Studies on early events of <i>Borrelia burgdorferi</i> -induced cytokine production in immunodeficient SCID mice by using a tissue chamber model for acute inflammation. <i>International Journal of Experimental Pathology</i> , 1995, 76, 111-23.	0.6	23
748	Transforming Growth Factor- β 1 and Laminin-111 Cooperate in the Regulation of Expression of Interleukin-6 and Interleukin-8 in Synovial Fibroblasts. <i>International Journal of Biomedical Science</i> , 2010, 6, 289-93.	0.5	1
750	Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications. <i>Frontiers in Immunology</i> , 2021, 12, 790122.	2.2	58
751	Overactive STAT3 Drives Accumulation of Disease-Associated CD21 ^{low} B Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
752	Rebalancing the unbalanced aged immune system – A special focus on zinc. <i>Ageing Research Reviews</i> , 2022, 74, 101541.	5.0	13
753	Characterization of clinical, laboratory, IL-6 serum levels, and IL-6-174 G/C genetic polymorphisms in patients with rheumatoid arthritis and Sjögren's syndrome. <i>Revista Da Associação Médica Brasileira</i> , 2021, 67, 1600-1604.	0.3	1
754	Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity. <i>Science Translational Medicine</i> , 2022, 14, eabi4888.	5.8	20
755	Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study. , 2022, 9, 26-30.		1
756	IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 866014.	1.3	87
757	The Role of TNF- α in the Pathogenesis of Temporomandibular Disorders. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 1801-1809.	0.6	12
759	Urticarial drug eruption following tocilizumab administration. <i>Journal of Cutaneous Immunology and Allergy</i> , 2022, 5, 186-187.	0.2	1
760	The role of B cells and their interactions with stromal cells in the context of inflammatory autoimmune diseases. <i>Autoimmunity Reviews</i> , 2022, 21, 103098.	2.5	9
762	Induction of interleukin-6 by interferon alfa and its abrogation by a serine protease inhibitor in patients with chronic hepatitis C. <i>Hepatology</i> , 1996, 23, 669-675.	3.6	8
763	Effector memory CD4 T cells induce damaging innate inflammation and autoimmune pathology by engaging CD40 and TNFR on myeloid cells.. <i>Science Immunology</i> , 2022, 7, eabk0182.	5.6	7
765	Distinct Immunological Profiles Help in the Maintenance of Salivary Secretory IgA Production in Mild Symptoms COVID-19 Patients. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
766	Inhibitory Effects of Cold Atmospheric Plasma on Inflammation and Tumor-Like Feature of Fibroblast-Like Synoviocytes from Patients with Rheumatoid Arthritis. <i>Inflammation</i> , 2022, 45, 2433-2448.	1.7	4
767	IL-6 is involved in thoracic ossification of the ligamentum flavum. <i>PLoS ONE</i> , 2022, 17, e0272357.	1.1	3
768	Disease mechanisms in preclinical rheumatoid arthritis: A narrative review. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7

#	ARTICLE	IF	CITATIONS
769	Peficitinib inhibits fibroblast-like synoviocyte activation and angiogenic vascular endothelial tube formation via inhibitory effects on PDGF and VEGF signaling in addition to JAK. <i>Journal of Pharmacological Sciences</i> , 2022, 150, 74-80.	1.1	3
770	Complement Regulation in Immortalized Fibroblast-like Synoviocytes and Primary Human Endothelial Cells in Response to SARS-CoV-2 Nucleocapsid Protein and Pro-Inflammatory Cytokine TNF α . <i>Life</i> , 2022, 12, 1527.	1.1	0
771	IL-2-based approaches to Treg enhancement. <i>Clinical and Experimental Immunology</i> , 2023, 211, 149-163.	1.1	15
773	The potential roles of JAK/STAT signaling in the progression of osteoarthritis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	13
774	High avidity state of leukocyte function-associated antigen-1 on rheumatoid synovial fluid T lymphocytes. <i>Journal of Immunology</i> , 1995, 155, 4118-4124.	0.4	21
775	The Regulation and Functional Consequence of Proinflammatory Cytokine Binding on Human Intestinal Epithelial Cells. <i>Journal of Immunology</i> , 1998, 161, 3675-3684.	0.4	112
776	Induction of Keratinocyte Proliferation and Lymphocytic Infiltration by In Vivo Introduction of the IL-6 Gene into Keratinocytes and Possibility of Keratinocyte Gene Therapy for Inflammatory Skin Diseases Using IL-6 Mutant Genes. <i>Journal of Immunology</i> , 1998, 161, 5633-5639.	0.4	68
777	Soluble IL-6 Receptor Potentiates the Antagonistic Activity of Soluble gp130 on IL-6 Responses. <i>Journal of Immunology</i> , 1998, 161, 6347-6355.	0.4	132
778	A Novel Role of IL-15 in the Development of Osteoclasts: Inability to Replace Its Activity with IL-2. <i>Journal of Immunology</i> , 1999, 162, 2754-2760.	0.4	101
779	Regulation of Cytokines, Cytokine Inhibitors, and Acute-Phase Proteins Following Anti-TNF- α Therapy in Rheumatoid Arthritis. <i>Journal of Immunology</i> , 1999, 163, 1521-1528.	0.4	368
780	Role of IL-6 in the Pleurisy and Lung Injury Caused by Carrageenan. <i>Journal of Immunology</i> , 1999, 163, 5094-5104.	0.4	90
781	Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes. <i>Cancer Reports</i> , 2023, 6, .	0.6	4
782	The Physiological and Pathophysiological Role of IL-6/STAT3-Mediated Signal Transduction and STAT3 Binding Partners in Therapeutic Applications. <i>Biological and Pharmaceutical Bulletin</i> , 2023, 46, 364-378.	0.6	5
783	The effect of non-surgical periodontal therapy on salivary IL-6 levels in patients with moderate to severe generalized chronic periodontitis. <i>Irish Journal of Medical Science</i> , 2023, 192, 2981-2986.	0.8	1
784	An insilico analysis to check the effect of novel drug molecules with Interleukin-6 on Rheumatoid arthritis. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
788	The Role of Interleukin (IL)-6/IL-6 Receptor Axis in Cancer. , 2023, , 137-164.		0